

|                                                                                                                                                                                                                                                                        |               |            |             |                                                                                         |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|------------|-------------|-----------------------------------------------------------------------------------------|
|                                                                                                                                                                                                                                                                        |               |            |             |                                                                                         |
| <b>Published, ongoing &amp; planned projects</b>                                                                                                                                                                                                                       |               |            |             | <b>Last update 15.07.2026</b>                                                           |
| <b>Title</b>                                                                                                                                                                                                                                                           | <b>Status</b> | <b>No.</b> | <b>Year</b> | <b>Download/Link</b>                                                                    |
| <b>AIHTA Project Reports</b>                                                                                                                                                                                                                                           |               |            |             |                                                                                         |
| Therapeutic conversation: The effectiveness of intensified physician-patient communication                                                                                                                                                                             | published     | 1          | 2006        | <a href="http://eprints.aihta.at/22/">http://eprints.aihta.at/22/</a>                   |
| Horizon Scanning System (HSS) - An Overview                                                                                                                                                                                                                            | published     | 2          | 2006        | <a href="http://eprints.aihta.at/586/">http://eprints.aihta.at/586/</a>                 |
| External manual. Part 1                                                                                                                                                                                                                                                | published     | 3          | 2007        | <a href="http://eprints.aihta.at/714/">http://eprints.aihta.at/714/</a>                 |
| Neonatal care of low-risk newborns. An approach to evidence-based health care planning in Styria                                                                                                                                                                       | published     | 4          | 2007        | <a href="http://eprints.aihta.at/693/">http://eprints.aihta.at/693/</a>                 |
| Role and positioning of university outpatient departments                                                                                                                                                                                                              | published     | 5          | 2007        | <a href="http://eprints.aihta.at/38/">http://eprints.aihta.at/38/</a>                   |
| Internal manual. Part 2 (2nd Ed.)                                                                                                                                                                                                                                      | published     | 6          | 2009        | <a href="http://eprints.aihta.at/713/">http://eprints.aihta.at/713/</a>                 |
| Mammography screening. Evidence-based evaluation of mammography-based breast cancer screening programmes                                                                                                                                                               | published     | 7          | 2007        | <a href="http://eprints.aihta.at/715/">http://eprints.aihta.at/715/</a>                 |
| Testing for HER2 positive breast cancer. Challenge for improvement of current conditions and practice                                                                                                                                                                  | published     | 8          | 2007        | <a href="http://eprints.aihta.at/716/">http://eprints.aihta.at/716/</a>                 |
| Economic evaluation of HPV vaccination in Austria                                                                                                                                                                                                                      | published     | 9          | 2007        | <a href="http://eprints.aihta.at/760/">http://eprints.aihta.at/760/</a>                 |
| Economic aspects of clinically effective and efficient models of health services in alcohol addiction treatment - Part I: International models and approaches of outcome measurement, Part 2: Selected models of integrated care and their evaluation, Part 3: ongoing | published     | 10         | 2009        | <a href="http://eprints.aihta.at/823/">http://eprints.aihta.at/823/</a>                 |
| Clinical and health economic registries in the field of cardiovascular, spinal and neurologic diseases. Methods and good practice strategies                                                                                                                           | published     | 11         | 2008        | <a href="http://eprints.aihta.at/788/">http://eprints.aihta.at/788/</a>                 |
| Back pain. Diagnosis and treatment according to evidence-based guidelines - options and limitations.                                                                                                                                                                   | published     | 12         | 2008        | <a href="http://eprints.aihta.at/794/">http://eprints.aihta.at/794/</a>                 |
| Clinical application of Tissue Engineering. An overview of International and Austrian Areas of Research with a critical analysis of selected applications                                                                                                              | published     | 13         | 2008        | <a href="http://eprints.aihta.at/807/">http://eprints.aihta.at/807/</a>                 |
| Horizon Scanning in Oncology - Concept Development for the Preparation of a Horizon Scanning System in Austria                                                                                                                                                         | published     | 14         | 2008        | <a href="http://eprints.aihta.at/798/">http://eprints.aihta.at/798/</a>                 |
| Outpatient Cardiac Rehabilitation. Part 1: Evaluation and Indicators. Part 2: Comparative analysis of various rehabilitation models and Phase III                                                                                                                      | published     | 15         | 2008        | <a href="http://eprints.aihta.at/800/">http://eprints.aihta.at/800/</a>                 |
| Clinical Pathways: Systematic Review of outcome parameters and effectiveness                                                                                                                                                                                           | published     | 16         | 2008        | <a href="http://eprints.aihta.at/801/">http://eprints.aihta.at/801/</a>                 |
| Clavicular Fractures - A systematic review about efficacy and safety of different treatment options                                                                                                                                                                    | published     | 17         | 2008        | <a href="http://eprints.aihta.at/816/">http://eprints.aihta.at/816/</a>                 |
| Statins for the Secondary Prevention of Cardiovascular Diseases: An Analysis of Expected Population Health Gains and Cost-Utility in Austria (Part 2 of the project 'Statins: A comparison between predicted and actual effects on population health in Austria        | published     | 18         | 2008        | <a href="http://eprints.aihta.at/803/">http://eprints.aihta.at/803/</a>                 |
| Have Statins Met Our Expectations? A Comparison of Expected Health Gains from Statins with Epidemiological Trends in Austria (Part 3 of the Project 'Statins: A Comparison Between Predicted and Actual Effects on Population Health in Austria').                     | published     | 19         | 2008        | <a href="http://eprints.aihta.at/804/">http://eprints.aihta.at/804/</a>                 |
| Folic acid fortification of flour in Austria - Risks and benefits                                                                                                                                                                                                      | published     | 20         | 2009        | <a href="http://eprints.aihta.at/847/">http://eprints.aihta.at/847/</a>                 |
| Evidence supported health service planning                                                                                                                                                                                                                             | published     | 21         | 2009        | <a href="http://eprints.aihta.at/843/">http://eprints.aihta.at/843/</a>                 |
| Reimbursement processes – An analysis of international practice models for maintaining the health benefit baskets of solidly financed health care systems                                                                                                              | published     | 22         | 2008        | <a href="http://eprints.aihta.at/817/">http://eprints.aihta.at/817/</a>                 |
| Classification of disease severity for neuro- and trauma rehabilitation - Part 1: instruments for stroke and traumatic brain injury                                                                                                                                    | published     | 23a        | 2009        | <a href="http://eprints.aihta.at/866/">http://eprints.aihta.at/866/</a>                 |
| Classification of disease severity for neuro- and trauma rehabilitation - Part 2: International experiences with quality / performance assessments and reimbursement                                                                                                   | published     | 23b        | 2009        | <a href="http://eprints.aihta.at/867/">http://eprints.aihta.at/867/</a>                 |
| Classification of disease severity for neuro- and trauma rehabilitation - Part 3: Status quo s in Austria                                                                                                                                                              | published     | 23c        | 2010        | <a href="http://eprints.aihta.at/879/">http://eprints.aihta.at/879/</a>                 |
| Coverage with Evidence Development - Experiences from selected countries                                                                                                                                                                                               | published     | 24         | 2009        | <a href="http://eprints.aihta.at/818/">http://eprints.aihta.at/818/</a>                 |
| Kyphoplasty and vertebroplasty for the treatment of osteoporotic vertebral compression fractures- observational study.                                                                                                                                                 | published     | 25         | 2010        | <a href="http://eprints.aihta.at/900/">http://eprints.aihta.at/900/</a>                 |
| Developing a decision aid on HPV-vaccination for young girls and women/ mothers                                                                                                                                                                                        | published     | 26         | 2009        | <a href="http://www.hpv-entscheidungshilfe.de">http://www.hpv-entscheidungshilfe.de</a> |
| Evaluations of child and adolescent psychiatry. (Part 1a) - Theory and practice about measurement dimensions, indicators and instruments.                                                                                                                              | published     | 27         | 2009        | <a href="http://eprints.aihta.at/846/">http://eprints.aihta.at/846/</a>                 |
| Child and adolescent psychiatry. (Part 1b) - A systematic review of health economic evaluations                                                                                                                                                                        | published     | 28         | 2009        | <a href="http://eprints.aihta.at/862/">http://eprints.aihta.at/862/</a>                 |
| Child and adolescent psychiatry. (Part 2) - Evaluation study at the University Department of Child and Adolescent Psychiatry (Christian-Doppler-Klinik) in Salzburg                                                                                                    | published     | 40         | 2010        | <a href="https://eprints.aihta.at/862/">https://eprints.aihta.at/862/</a>               |
| Telemedicine in Stroke Management. Systematic Review.                                                                                                                                                                                                                  | published     | 29         | 2009        | <a href="http://eprints.aihta.at/844/">http://eprints.aihta.at/844/</a>                 |
| Tocolysis in preterm labour - A systematic review of evidence-based guidelines, effectiveness and health economic evaluations                                                                                                                                          | published     | 30         | 2009        | <a href="http://eprints.aihta.at/825/">http://eprints.aihta.at/825/</a>                 |
| Outpatient cardiac rehabilitation. Part 3a: Retrospective cohort study (with/without phase III rehabilitation - Explorative analysis and developing of an evaluation plan                                                                                              | published     | 31a        | 2010        | <a href="http://eprints.aihta.at/875/">http://eprints.aihta.at/875/</a>                 |
| Outpatient cardiac rehabilitation. Part 3b: Retrospective cohort study (with/without phase III rehabilitation - Application of the evaluation plan                                                                                                                     | published     | 31b        | 2010        | <a href="http://eprints.aihta.at/876/">http://eprints.aihta.at/876/</a>                 |
| Horizon scanning in oncology - Part 2: From pilot to routine                                                                                                                                                                                                           | ongoing       | 32         |             | <a href="#">siehe HSS Publikationen ganz unten</a>                                      |
| Artificial food colours and Hyperactivity                                                                                                                                                                                                                              | published     | 34         | 2009        | <a href="http://eprints.aihta.at/848/">http://eprints.aihta.at/848/</a>                 |
| Status quo Mammography screening. Evaluation results from organised programs                                                                                                                                                                                           | published     | 35         | 2009        | <a href="http://eprints.aihta.at/863/">http://eprints.aihta.at/863/</a>                 |
| Evaluation of diagnostic technologies – background, challenges, methods                                                                                                                                                                                                | published     | 36         | 2010        | <a href="http://eprints.aihta.at/898/">http://eprints.aihta.at/898/</a>                 |
| Impact from HTA-research for the Austrian health care system. Part 1: Overview - Update                                                                                                                                                                                | published     | 37a        | 2010        | <a href="http://eprints.aihta.at/877/">http://eprints.aihta.at/877/</a>                 |
| Impact from HTA-research for the Austrian health care system. Part 2: Results of the empirical survey                                                                                                                                                                  | published     | 37b        | 2011        | <a href="http://eprints.aihta.at/907/">http://eprints.aihta.at/907/</a>                 |
| Acquisition Processes of Certain Product Groups in Hospitals - Orthopaedic and Cardiac Implants                                                                                                                                                                        | published     | 38         | 2009        | <a href="http://eprints.aihta.at/864/">http://eprints.aihta.at/864/</a>                 |

| Title                                                                                                                                                                                                                             | Status        | No. | Year | Download/Link                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-----|------|---------------------------------------------------------------------------|
| Haemocompletan® P and Fibrogammin® P in acquired hypofibrinogenemia                                                                                                                                                               | published     | 39  | 2009 | <a href="http://eprints.aihta.at/870/">http://eprints.aihta.at/870/</a>   |
| Screening for Colorectal Cancer. Part 1: Screening-Tests and Project Design                                                                                                                                                       | published     | 41a | 2010 | <a href="http://eprints.aihta.at/873/">http://eprints.aihta.at/873/</a>   |
| Screening for Colorectal Cancer. Part 2: Health economic evaluations and developments of costs                                                                                                                                    | published     | 41b | 2010 | <a href="http://eprints.aihta.at/874/">http://eprints.aihta.at/874/</a>   |
| IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Principles of standardised work in HTA (WP1.2)                                                                                                   | published     | 44a | 2011 | <a href="http://eprints.aihta.at/932/">http://eprints.aihta.at/932/</a>   |
| IFEDH - Innovative Framework for Evidence Based Decision Making in Health Care - Glossary of terms (WP2.1)                                                                                                                        | finished      | 44b | 2011 | not published                                                             |
| Reorientation of the Austrian parent-child preventive care programme. Part 1: Epidemiology - incidence of risk factors and diseases in pregnancy and early childhood                                                              | published     | 45a | 2011 | <a href="http://eprints.aihta.at/912/">http://eprints.aihta.at/912/</a>   |
| Reorientation of the Austrian parent-child preventive care programme. Part 2: International Policies, approaches and screening strategies to "normal" and "risk experiences" during pregnancy and early childhood to school entry | published     | 45b | 2011 | <a href="http://eprints.aihta.at/913/">http://eprints.aihta.at/913/</a>   |
| Reorientation of the Austrian parent-child preventive care programme. Part 3: Status quo of the financing and cost structures of parent-child services in Austria                                                                 | published     | 45c | 2011 | <a href="http://eprints.aihta.at/914/">http://eprints.aihta.at/914/</a>   |
| Reorientation of the Austrian parent-child preventive care programme. Part 4: Synthesis of Parts 1-3, Recommendations                                                                                                             | published     | 45d | 2011 | <a href="http://eprints.aihta.at/915/">http://eprints.aihta.at/915/</a>   |
| Gamma Knife versus adapted linear accelerators: A comparison of two radiosurgical applications                                                                                                                                    | published     | 47  | 2010 | <a href="http://eprints.aihta.at/901/">http://eprints.aihta.at/901/</a>   |
| Strengthening the evidence base for a learning health system - Inspirations from good practice for capacity building in health services research and public health research                                                       | published     | 48  | 2011 | <a href="http://eprints.aihta.at/908/">http://eprints.aihta.at/908/</a>   |
| Quality of care in oncology and its measurement                                                                                                                                                                                   | published     | 49a | 2011 | <a href="http://eprints.aihta.at/934/">http://eprints.aihta.at/934/</a>   |
| Generic indicators for process quality in oncological care. A compendium                                                                                                                                                          | published     | 49b | 2012 | <a href="http://eprints.aihta.at/946/">http://eprints.aihta.at/946/</a>   |
| Reorientation of the Austrian parent-child preventive care programme. Part 5: Preterm birth                                                                                                                                       | published     | 50  | 2012 | <a href="http://eprints.aihta.at/939/">http://eprints.aihta.at/939/</a>   |
| Systematic review of the efficacy and safety of treatments for varicose veins of the lower extremity                                                                                                                              | published     | 51  | 2011 | <a href="http://eprints.aihta.at/930/">http://eprints.aihta.at/930/</a>   |
| Appraisal of the quality and accuracy of written consumer health information for patients with chronic myeloid leukaemia on treatment-regimens with dasatinib, imatinib or nilotinib                                              | published     | 52  | 2012 | <a href="http://eprints.aihta.at/953/">http://eprints.aihta.at/953/</a>   |
| Reorientation of the Austrian parent-child preventive care programme. Part 6: Health visiting services in the international context and implementation options for Austria                                                        | published     | 53  | 2012 | <a href="http://eprints.aihta.at/947/">http://eprints.aihta.at/947/</a>   |
| Reorientation of the Austrian parent-child preventive care programme. Part 7: Options for an electronic implementation                                                                                                            | published     | 54  | 2012 | <a href="http://eprints.aihta.at/948/">http://eprints.aihta.at/948/</a>   |
| Reorientation of the Austrian parent-child preventive care programme. Part 8: Budget Impact Analysis                                                                                                                              | published     | 55  | 2012 | <a href="http://eprints.aihta.at/949/">http://eprints.aihta.at/949/</a>   |
| Occupational therapy in Austria                                                                                                                                                                                                   | published     | 56  | 2012 | <a href="http://eprints.aihta.at/972/">http://eprints.aihta.at/972/</a>   |
| Disinvestment. Overview of disinvestment experiences and challenges in selected countries.                                                                                                                                        | published     | 57  | 2011 | <a href="http://eprints.aihta.at/926/">http://eprints.aihta.at/926/</a>   |
| Standards on how to parameterise models via published literature - Input of the LBI HTA for IFEDH workpackage 4                                                                                                                   | published     | 58  | 2012 | <a href="http://eprints.aihta.at/990/">http://eprints.aihta.at/990/</a>   |
| Occupational therapy Part 3 – Occupational therapy for patients after stroke                                                                                                                                                      | published     | 59  | 2012 | <a href="http://eprints.aihta.at/973/">http://eprints.aihta.at/973/</a>   |
| Occupational Therapy Part 4 for Dementia and Part V for Depression                                                                                                                                                                | published     | 60  | 2012 | <a href="http://eprints.aihta.at/974/">http://eprints.aihta.at/974/</a>   |
| Horizon Scanning in Oncology - Impact Evaluation                                                                                                                                                                                  | published     | 61  | 2012 | <a href="http://eprints.aihta.at/969/">http://eprints.aihta.at/969/</a>   |
| Reorientation of the Austrian parent-child preventive care programme - Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)                                                                   | published     | 62  | 2013 | <a href="http://eprints.aihta.at/996/">http://eprints.aihta.at/996/</a>   |
| (III) Health and access to health care in homeless people: A literature review                                                                                                                                                    | published     | 63  | 2012 | <a href="http://eprints.aihta.at/980/">http://eprints.aihta.at/980/</a>   |
| Day Surgery: A Systematic Overview                                                                                                                                                                                                | published     | 64  | 2012 | <a href="http://eprints.aihta.at/987/">http://eprints.aihta.at/987/</a>   |
| Screening for Colorectal Cancer. Part 1: Screening Tests and Program Design (3. updated edition)                                                                                                                                  | published     | 41a | 2012 | <a href="http://eprints.aihta.at/981/">http://eprints.aihta.at/981/</a>   |
| Screening for Colorectal Cancer. Part 2: Health economic evaluations and cost dynamics (2. updated edition)                                                                                                                       | published     | 41b | 2012 | <a href="http://eprints.aihta.at/982/">http://eprints.aihta.at/982/</a>   |
| Screening for Colorectal Cancer. Part 3: update von Teil 1 (41 a) und Teil 2 (41 b), Quality of screening colonoscopy                                                                                                             | published     | 41c | 2013 | <a href="http://eprints.aihta.at/983/">http://eprints.aihta.at/983/</a>   |
| Marketing Authorisations under Exceptional Circumstances for Oncology Drugs                                                                                                                                                       | published     | 65  | 2013 | <a href="http://eprints.aihta.at/992/">http://eprints.aihta.at/992/</a>   |
| Outpatient cardiac rehabilitation; Part 6: Scientific monitoring of the "Multi-centre, prospective cohort study with two control groups (with/without phase III)"                                                                 | abgeschlossen | 66  |      | not published                                                             |
| „Mental Health“ rehabilitation for children and adolescents – A literature overview on indications, outcomes and evaluation instruments                                                                                           | published     | 67  | 2013 | <a href="http://eprints.aihta.at/1012/">http://eprints.aihta.at/1012/</a> |
| Identifying ineffective interventions and health technologies: models and their implementation                                                                                                                                    | published     | 68  | 2013 | <a href="http://eprints.aihta.at/1014/">http://eprints.aihta.at/1014/</a> |
| Treatment by clinical psychologists. Part 1: Overview of training requirements and systematic stakeholder analysis on delineation of areas of responsibility and treatment methods.                                               | published     | 69a | 2013 | <a href="http://eprints.aihta.at/1018/">http://eprints.aihta.at/1018/</a> |
| Treatment by clinical psychologists. Part 2: Literature overview on methods of treatment and areas of application.                                                                                                                | published     | 69b | 2013 | <a href="http://eprints.aihta.at/1019/">http://eprints.aihta.at/1019/</a> |
| Occupational therapy in children. Part 1 – Literature review on indications, utilisation and recommendations                                                                                                                      | published     | 70  | 2013 | <a href="http://eprints.aihta.at/1016/">http://eprints.aihta.at/1016/</a> |
| Cost- and Budget-Impact-Analysis of an Increase in Day Surgery for Selected Indications                                                                                                                                           | published     | 71  | 2014 | <a href="http://eprints.aihta.at/1035/">http://eprints.aihta.at/1035/</a> |
| p16/Ki-67 Dual Stain in cytological screening of cervical cancer: A systematic literature review of clinical studies based on a review of methodological approaches for assessing biomarkers                                      | published     | 72  | 2013 | <a href="http://eprints.aihta.at/1009/">http://eprints.aihta.at/1009/</a> |
| Evidence requirements for the authorisation and reimbursement of high risk medical devices in USA, Australia and Canada                                                                                                           | published     | 73  | 2013 | <a href="http://eprints.aihta.at/1017/">http://eprints.aihta.at/1017/</a> |
| Proton- and Carbon Ion therapy                                                                                                                                                                                                    | published     | 74  | 2013 | <a href="http://eprints.aihta.at/1021/">http://eprints.aihta.at/1021/</a> |
| Sustainability of inpatient psychiatric rehabilitation for adults: systematic review                                                                                                                                              | published     | 75  | 2014 | <a href="http://eprints.aihta.at/1025/">http://eprints.aihta.at/1025/</a> |
| Positron emission tomography/ Computer tomography (PET/ CT): need-assessment for planning                                                                                                                                         | published     | 77  | 2015 | <a href="http://eprints.aihta.at/1045/">http://eprints.aihta.at/1045/</a> |
| Acupuncture - areas of application, current evidence and proven indications                                                                                                                                                       | published     | 78  | 2014 | <a href="http://eprints.aihta.at/1042/">http://eprints.aihta.at/1042/</a> |
| Vasoprotectives: Efficacy and safety of capillary stabilising agents for venous insufficiency or haemorrhoids                                                                                                                     | published     | 79  | 2014 | <a href="http://eprints.aihta.at/1047/">http://eprints.aihta.at/1047/</a> |
| Criteria and recommendations for an adequate use of Magnetic Resonance Imaging (MRI)                                                                                                                                              | published     | 80  | 2014 | <a href="http://eprints.aihta.at/1043/">http://eprints.aihta.at/1043/</a> |
| Lithuania: HTA Training                                                                                                                                                                                                           | finished      | 81  |      | not published                                                             |
| Adequacy of MRI 2                                                                                                                                                                                                                 | finished      | 82  |      | not published                                                             |
| Effects of (im)material incentives on health behaviour, Part I: Definitions, theories and models and Part II: Overview of reviews covering 4 health issues                                                                        | published     | 83  | 2015 | <a href="http://eprints.aihta.at/1078/">http://eprints.aihta.at/1078/</a> |

| Title                                                                                                                                                                              | Status    | No.            | Year | Download/Link                                                             |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|----------------|------|---------------------------------------------------------------------------|
| Robotic Surgery                                                                                                                                                                    | published | 84             | 2015 | <a href="http://eprints.aihta.at/1077/">http://eprints.aihta.at/1077/</a> |
| Endovascular stroke therapy                                                                                                                                                        | finished  | 85             |      | not published                                                             |
| Patient- and citizen participation in HTA processes - Good Practice                                                                                                                | published | 86             | 2016 | <a href="http://eprints.aihta.at/1088/">http://eprints.aihta.at/1088/</a> |
| Nudging -Behavioral Sciences applied to the Big Four Public Health issues                                                                                                          | published | 83/ Addendum   | 2015 | <a href="http://eprints.aihta.at/1078/">http://eprints.aihta.at/1078/</a> |
| Mechanical thrombectomy in acute ischemic stroke. Patient characteristics, structural requirements and (differential) diagnosis                                                    | published | 87             | 2016 | <a href="http://eprints.aihta.at/1084/">http://eprints.aihta.at/1084/</a> |
| New concept for primary care (Supply mandates)                                                                                                                                     | published | 88             | 2016 | <a href="http://eprints.aihta.at/1110/">http://eprints.aihta.at/1110/</a> |
| Outpatient cardiac rehabilitation, Part 6: Economic evaluation                                                                                                                     | published | 89             | 2016 | <a href="http://eprints.aihta.at/1102/">http://eprints.aihta.at/1102/</a> |
| Options to identify inappropriate use of MRI, Part 3                                                                                                                               | published | 80c            | 2015 | <a href="http://eprints.aihta.at/1159/">http://eprints.aihta.at/1159</a>  |
| Opportunities and strategies to drive appropriate use of MRI in Austria. Part 2                                                                                                    | published | 80b            | 2015 | <a href="http://eprints.aihta.at/1090/">http://eprints.aihta.at/1090/</a> |
| Outpatient cardiac rehabilitation, Part 6: Scientific monitoring of the Multi-centre, prospective cohort study with two control groups (with/without phase III)                    | published | 90             | 2016 | <a href="http://eprints.aihta.at/1101/">http://eprints.aihta.at/1101/</a> |
| Reorientation of the Austrian parent-child preventive care programme. Part 12: Economic evaluation of selected screenings during pregnancy                                         | published | 91             | 2017 | <a href="http://eprints.aihta.at/996/">http://eprints.aihta.at/996/</a>   |
| Reorientation of the Austrian parent-child preventive care programme - Part 9: Evidence-based screening guidelines for pregnant women and children (0 – 6 yrs.)                    | published | 62/Update 2016 | 2016 | <a href="http://eprints.aihta.at/1112/">http://eprints.aihta.at/1112/</a> |
| Re-orientation of the Austrian parent-child preventive care programme. Part 11: Screening recommendations of the expert working group for pregnancy                                | published | 92             | 2019 | <a href="http://eprints.aihta.at/1163/">http://eprints.aihta.at/1163/</a> |
| Legally recognized psychotherapy methods in Austria – effect factors, indications, setting specific aspects                                                                        | published | 93             | 2017 | <a href="http://eprints.aihta.at/1143/">http://eprints.aihta.at/1143/</a> |
| Telekardiologie - Map Ö and evaluation methods: Work in Progress                                                                                                                   | finished  | 94             |      | not published                                                             |
| Transcatheter Aortic Valve Implantation Part 1: A systematic review of economic evaluations                                                                                        | published | 95a            | 2017 | <a href="http://eprints.aihta.at/1139/">http://eprints.aihta.at/1139</a>  |
| Social Return on Investment for Child and Adolescence Health: Outcomes, Methods and Economic Parameters                                                                            | published | 96             | 2017 | <a href="http://eprints.aihta.at/1142/">http://eprints.aihta.at/1142/</a> |
| Perinatal Care at the threshold of viability. Part I Resource planning for Neonatal Care Units: clinical outcomes and resource needs                                               | published | 97a            | 2018 | <a href="http://eprints.aihta.at/1146/">http://eprints.aihta.at/1146/</a> |
| Part II (Good) Practice Models to handle Ethical, Organizational, and Social Challenges                                                                                            |           |                |      |                                                                           |
| Perinatal Care at the threshold of viability Part II: Decision-making at the threshold of viability and ethical challenges at Neonatal Intensive Care Units (NICUs)                | published | 97b            | 2018 | <a href="http://eprints.aihta.at/1148/">http://eprints.aihta.at/1148/</a> |
| Transthoracic Echocardiography (TAVI) Part 1: Use in Austria and Guideline Recommendations for Appropriate Use                                                                     | published | 98             |      | <a href="http://eprints.aihta.at/1158/">http://eprints.aihta.at/1158/</a> |
| Transcatheter Aortic Valve Implantation (TAVI) Part 2: Frequency, Patient Collective, and Geographic Variation Over Time in Austria                                                | published | 95b            | 2017 | <a href="http://eprints.aihta.at/1141/">http://eprints.aihta.at/1141/</a> |
| PET/PET-CT Evidence for need based planning in Germany and Austria                                                                                                                 | published | 77/Update 2018 | 2018 | <a href="http://eprints.aihta.at/1178/">http://eprints.aihta.at/1178/</a> |
| 'Dropouts in psychotherapies – Theoretical reflections and counter-strategies                                                                                                      | published | 100            | 2018 | <a href="http://eprints.aihta.at/1157/">http://eprints.aihta.at/1157/</a> |
| Carbon ion beam radiotherapy (CIRT) for cancer treatment: a systematic review of effectiveness and safety for 12 oncologic indications                                             | published | 101            | 2018 | <a href="http://eprints.aihta.at/1174/">http://eprints.aihta.at/1174/</a> |
| Genexpressionstest Mammaprint® zur Entscheidungs-unterstützung für/gegen adjuvante Chemotherapie bei primärem Brustkrebs                                                           | published | 102            | 2018 | <a href="http://eprints.aihta.at/1147/">http://eprints.aihta.at/1147/</a> |
| Screening of fetal trisomes 21, 18 and 13 by noninvasive prenatal testing                                                                                                          | published | 103            | 2018 | <a href="http://eprints.aihta.at/1153/">http://eprints.aihta.at/1153/</a> |
| Inhalation sedation with laughing gas (N2O) in dentistry – organisational and professional aspects and a systematic review of efficacy and safety                                  | published | 105            | 2018 | <a href="http://eprints.aihta.at/1182/">http://eprints.aihta.at/1182/</a> |
| Screening programmes for children and adolescents aged 6-14 years in selected countries and recommendations from evidence-based guidelines                                         | published | 106            | 2018 | <a href="http://eprints.aihta.at/1212/">http://eprints.aihta.at/1212/</a> |
| Stereotactic radiotherapy (Cyberknife®), proton beam therapy and irreversible (electroporation Nanoknife®) for localised prostate cancer (PCa): a systematic review                | published | 107            | 2018 | <a href="http://eprints.aihta.at/1165/">http://eprints.aihta.at/1165</a>  |
| Robot-assisted surgery: A systematic review of effectiveness and safety in thoracic and visceral surgery                                                                           | published | 108            | 2019 | <a href="http://eprints.aihta.at/1198/">http://eprints.aihta.at/1198/</a> |
| Pricing and reimbursement in the inpatient sector in Austria: Approaches for a transparent and evidence-based process taking into account international experience                 | published | 109            | 2019 | <a href="http://eprints.aihta.at/1183/">http://eprints.aihta.at/1183/</a> |
| EditTechnology Forecast: advanced therapies in late clinical research, EMA approval or clinical application via hospital exemption                                                 | published | 111            |      | <a href="http://eprints.aihta.at/1197/">http://eprints.aihta.at/1197/</a> |
| Natalizumab as treatment for Multiple Sclerosis: a systematic review                                                                                                               | published | 112            | 2019 | <a href="http://eprints.aihta.at/1190/">http://eprints.aihta.at/1190/</a> |
| Uptake of mental health care benefits (co-) funded by the Tyrolean health insurance (Village)                                                                                      | published | 113a           | 2019 | <a href="http://eprints.aihta.at/1180/">http://eprints.aihta.at/1180/</a> |
| Prevalence of mental disorders and uptake of mental health services in Tyrol: An analysis of epidemiological literature and administrative data from the Tyrolean health insurance | published | 113b           | 2019 | <a href="http://eprints.aihta.at/1181/">http://eprints.aihta.at/1181/</a> |
| Evaluation methods for benefit assessment of easily accessible outpatient health centres for vulnerable groups - Focus: homeless and uninsured persons                             | published | 114            | 2019 | <a href="http://eprints.aihta.at/1195/">http://eprints.aihta.at/1195/</a> |
| Transcatheter aortic valve implantation (TAVI) for the treatment of patients at intermediate surgical risk TRANSCATHETER AORTIC VALVE IMPLANTATION (TAVI)                          | published | 115            | 2019 | <a href="http://eprints.aihta.at/1188/">http://eprints.aihta.at/1188/</a> |
| C-reactive protein point-of-care testing (CRP POCT) to guide antibiotic prescribing in primary care settings for acute respiratory tract infections. EUnetHTA-Report               | published | 116            | 2019 | <a href="http://eprints.aihta.at/1194/">http://eprints.aihta.at/1194/</a> |
| 3D-Druck von maßgefertigten oder individualisierbaren Implantaten und Schnittschablonen: EUnetHTA-Report                                                                           | published | 117            | 2019 | <a href="http://eprints.aihta.at/1209/">http://eprints.aihta.at/1209/</a> |
| Screening for Diabetes mellitus: guideline recommendations                                                                                                                         | published | 118            | 2019 | <a href="http://eprints.aihta.at/1213/">http://eprints.aihta.at/1213/</a> |
| Irreversible Elektroporation (IRE) bei Bauchspeicheldrüsen- und Leberkrebs. EUnetHTA-Report                                                                                        | published | 119            | 2019 | <a href="http://eprints.aihta.at/1211/">http://eprints.aihta.at/1211/</a> |
| Public & philanthropic financial contribution to the development of new drugs: Methodology & 3 Case Studies                                                                        | published | 120            | 2019 | <a href="http://eprints.aihta.at/1214/">http://eprints.aihta.at/1214/</a> |
| Prevention of cervical cancer in Austria – Implementation of HPV testing into the existing screening programme                                                                     | published | 121            | 2019 | <a href="http://eprints.aihta.at/1223/">http://eprints.aihta.at/1223/</a> |
| Rehabilitation for children and adolescents in Austria: A systematic analysis of evaluation methodologies                                                                          | published | 122            | 2019 | <a href="http://eprints.aihta.at/1222/">http://eprints.aihta.at/1222</a>  |
| Screening programmes for children and adolescents aged 6-18 years, Part II                                                                                                         | finished  | 123            |      | not published                                                             |
| POCT/ Point of Care Tests: D-Dimer und Troponin                                                                                                                                    | published | 124            | 2019 | <a href="http://eprints.aihta.at/1224/">http://eprints.aihta.at/1224/</a> |
| Minimum volume standards for quality assurance in day surgery                                                                                                                      | published | 125            | 2019 | <a href="http://eprints.aihta.at/1225/">http://eprints.aihta.at/1225/</a> |
| Health Services Research in Oncology: Patients with Non-small Cell Lung Cancer (NSCLC) treated with Anti-PD1/PD-L1 Therapy in Real-World Practice                                  | published | 126            | 2020 | <a href="https://eprints.aihta.at/1227">https://eprints.aihta.at/1227</a> |
| Health Services Research in Oncology Part I: End-of-Life Care                                                                                                                      | published | 127            | 2020 | <a href="http://eprints.aihta.at/1233">http://eprints.aihta.at/1233</a>   |
| Robotics and functional electrical stimulation for stroke rehabilitation                                                                                                           | published | 128            | 2020 | <a href="https://eprints.aihta.at/1302">https://eprints.aihta.at/1302</a> |

| Title                                                                                                                                                                                                                                           | Status     | No.             | Year | Download/Link                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----------------|------|-----------------------------------------------------------------------------|
| Home treatment in child and adolescent psychiatry: An analysis of effectiveness and integrated care                                                                                                                                             | published  | 129             | 2020 | <a href="http://eprints.aihta.at/1275/">http://eprints.aihta.at/1275/</a>   |
| Molecular genetic diagnostics as a triage mechanism in cardiology using the example of familial hypercholesterolemia: Organisational and ethical implications (part 1) and economic effects (part 2)                                            | published  | 130             | 2020 | <a href="http://eprints.aihta.at/1281/">http://eprints.aihta.at/1281/</a>   |
| Lung cancer screening in risk groups Systematic review(s) of effectiveness and utility (part 1)                                                                                                                                                 | published  | 132a            | 2020 | <a href="http://eprints.aihta.at/1282/">http://eprints.aihta.at/1282/</a>   |
| Lung cancer screening in risk groups Systematic review(s) of Costs and budgetary consequences (part 2)                                                                                                                                          | published  | 132b            | 2020 | <a href="https://eprints.aihta.at/1283">https://eprints.aihta.at/1283</a>   |
| Effectiveness of music therapy                                                                                                                                                                                                                  | published  | 133             | 2020 | <a href="http://eprints.aihta.at/1280/">http://eprints.aihta.at/1280/</a>   |
| Framework for reimbursement decisions of digital health technologies (mHealth) and its (retrospective) application on selected examples                                                                                                         | published  | 134             | 2020 | <a href="https://eprints.aihta.at/1279">https://eprints.aihta.at/1279</a>   |
| Epidemiology of long COVID: a preliminary report. German short version of the original KCE report                                                                                                                                               | published  | 135a            | 2021 | <a href="https://eprints.aihta.at/1321">https://eprints.aihta.at/1321</a>   |
| Long COVID care pathways: a systematic review                                                                                                                                                                                                   | published  | 135b            | 2021 | <a href="https://eprints.aihta.at/1342">https://eprints.aihta.at/1342</a>   |
| Evidence-based reimbursement processes in Europe Part 1: Reimbursement decisions for medical procedures in Austria. An analysis of factors – besides clinical evidence – influencing reimbursement decisions for the hospital benefit catalogue | finished   | 136             |      | not published                                                               |
| Evidence-based reimbursement processes in Europe Part 2: A comparative analysis of selected medical devices in German and Austrian hospitals and possible influencing factors                                                                   | finished   | 137             |      | not published                                                               |
| (Good) practice organizational models using real-world evidence for public funding of high prized therapies                                                                                                                                     | published  | 138             | 2021 | <a href="https://eprints.aihta.at/1329">https://eprints.aihta.at/1329</a>   |
| National strategies and programmes for preventing and managing non-communicable diseases in selected countries                                                                                                                                  | published  | 139             |      | <a href="https://eprints.aihta.at/1349/">https://eprints.aihta.at/1349/</a> |
| Contrasting evidence from pivotal trials with real world evidence for treatment with nivolumab in malignant melanoma.                                                                                                                           | published  | 140             | 2021 | <a href="https://eprints.aihta.at/1341">https://eprints.aihta.at/1341</a>   |
| Process and evaluation of digital health applications in the context of "Symptom Checkers"                                                                                                                                                      | published  | 141             | 2021 | <a href="https://eprints.aihta.at/1348/">https://eprints.aihta.at/1348/</a> |
| The economic and societal dimension of parental mental illness                                                                                                                                                                                  | published  | 142             | 2021 | <a href="https://eprints.aihta.at/1351/">https://eprints.aihta.at/1351/</a> |
| Telemonitoring in Austrian diabetes care: A systematic analysis of evaluation methodologies                                                                                                                                                     | published  | 143             | 2022 | <a href="https://eprints.aihta.at/1370/">https://eprints.aihta.at/1370/</a> |
| Osteopathy: effectiveness and safety for musculoskeletal pain and overview of training and quality requirements                                                                                                                                 | published  | 144             | 2022 | <a href="https://eprints.aihta.at/1416">https://eprints.aihta.at/1416</a>   |
| Risk-based breast cancer screening in Austria: a systematic analysis of predictive models to assess the individual breast cancer risk, their utility and applicability in breast cancer screening programs                                      | published  | 145             | 2022 | <a href="https://eprints.aihta.at/1402/">https://eprints.aihta.at/1402/</a> |
| CAR-T cell therapies (axicabtagen ciloleucel/Yescarta®) or tisagenlecleucel/Kymriah®): Contrasting pivotal studies with data from utility studies                                                                                               | published  | 146             | 2022 | <a href="https://eprints.aihta.at/1415/">https://eprints.aihta.at/1415/</a> |
| Long Covid – Versorgungspfade und Versorgungsstrukturen Update                                                                                                                                                                                  | publiziert | 135b/Update     | 2022 | <a href="https://eprints.aihta.at/1408/">https://eprints.aihta.at/1408/</a> |
| Support for children with mentally ill parents in Tyrol: Summary results of the Village Project                                                                                                                                                 | finished   | 147             |      | not published                                                               |
| Perinatal and infant mental health care models and pathways                                                                                                                                                                                     | published  | 148             | 2022 | <a href="https://eprints.aihta.at/1420/">https://eprints.aihta.at/1420/</a> |
| Child and adolescent mental health care models                                                                                                                                                                                                  | published  | 149             | 2022 | <a href="https://eprints.aihta.at/1418/">https://eprints.aihta.at/1418/</a> |
| Quality Registries in Dementia Care: Mapping of Registries to improve Quality and Service Delivery                                                                                                                                              | published  | 150             | 2022 | <a href="https://eprints.aihta.at/1419/">https://eprints.aihta.at/1419/</a> |
| Perinatal and infant mental health care in Austria: A mapping of existing prevention, screening and care structures, with a specific focus on Tyrol                                                                                             | published  | 151             | 2023 | <a href="https://eprints.aihta.at/1437/">https://eprints.aihta.at/1437/</a> |
| Oral and parenteral preexposure prophylaxis (PrEP) to prevent HIV in people at risk: a systematic review of clinical effectiveness and safety with assessment of organisational, economic, patients/social, ethical and legal elements          | published  | 152             | 2023 | <a href="https://eprints.aihta.at/1436/">https://eprints.aihta.at/1436/</a> |
| Robot-assisted surgery: A systematic review of effectiveness and safety in thoracic and visceral surgery. Update 2023                                                                                                                           | published  | 108/Update 2023 | 2023 | <a href="https://eprints.aihta.at/1461/">https://eprints.aihta.at/1461/</a> |
| Economic dimensions of community nursing                                                                                                                                                                                                        | published  | 153             | 2023 | <a href="https://eprints.aihta.at/1470/">https://eprints.aihta.at/1470/</a> |
| Mental Health Services Uptake in Women Before and During Pregnancy until One Year after Birth: An Analysis of Austrian Health Insurance Data' (im Rahmen des FWF Projektes 'Connecting Minds' erstellt)                                         | published  | 154             | 2023 | <a href="https://eprints.aihta.at/1535/">https://eprints.aihta.at/1535/</a> |
| Review of strategies regarding target group accessibility, participation motivation, and adherence in prevention programmes for overweight or obese children, adolescents, and adults                                                           | published  | 155             | 2023 | <a href="https://eprints.aihta.at/1486/">https://eprints.aihta.at/1486/</a> |
| Image-guided spinal injections in treatment of chronic spinal pain: an overview of evidence-based guideline recommendations and specific focus on guidance techniques                                                                           | published  | 156             | 2023 | <a href="https://eprints.aihta.at/1477/">https://eprints.aihta.at/1477/</a> |
| Registries in Austria and their usage for healthcare improvement                                                                                                                                                                                | published  | 157             | 2023 | <a href="https://eprints.aihta.at/1489/">https://eprints.aihta.at/1489/</a> |
| The Role of Public Contributions to the Development of Health Innovations                                                                                                                                                                       | published  | 158             | 2024 | <a href="https://eprints.aihta.at/1499/">https://eprints.aihta.at/1499/</a> |
| Point of Care Tests (POCT): D-Dimer and Troponin. Update 2024                                                                                                                                                                                   | published  | 1. Update 2024  | 2024 | <a href="https://eprints.aihta.at/1524/">https://eprints.aihta.at/1524/</a> |
| Stereotactic radiotherapy, proton therapy and irreversible electroporation for the treatment of localised prostate cancer                                                                                                                       | published  | 107/ 1. Update  | 2024 | <a href="https://eprints.aihta.at/1530/">https://eprints.aihta.at/1530/</a> |
| Mental health screening of adults in primary care                                                                                                                                                                                               | published  | 159             | 2024 | <a href="https://eprints.aihta.at/1544">https://eprints.aihta.at/1544</a>   |
| Strategies to reduce weight stigmatisation of people with overweight or obesity in the healthcare sector                                                                                                                                        | published  | 160             | 2024 | <a href="https://eprints.aihta.at/1547/">https://eprints.aihta.at/1547/</a> |
| ASSESS-DHT: Telehealth in diabetes: EU mapping and systematic evaluation of organisational aspects                                                                                                                                              | ongoing    | 161             |      | <a href="https://eprints.aihta.at/1555/">https://eprints.aihta.at/1555/</a> |
| Oncological Breast Cancer Care in Selected European Countries - Organisation of healthcare infrastructures and medical service provision                                                                                                        | published  | 162             | 2024 | <a href="https://eprints.aihta.at/1545/">https://eprints.aihta.at/1545/</a> |
| Threshold values in health economic evaluations and decision-making                                                                                                                                                                             | published  | 163             | 2024 | <a href="https://eprints.aihta.at/1549/">https://eprints.aihta.at/1549/</a> |
| Artificial Intelligence in health care with a focus on hospitals: Methodological considerations for Health Technology Assessment. A Scoping Review.                                                                                             | published  | 164             | 2024 | <a href="https://eprints.aihta.at/1546/">https://eprints.aihta.at/1546/</a> |
| Trauma Care: Teaching Recovery Technique (TRT) to refugees: Systematic Review and Evaluation of Austrian TRT-Programme at AFYA                                                                                                                  | published  | 165             | 2025 | <a href="https://eprints.aihta.at/1563/">https://eprints.aihta.at/1563/</a> |
| CAR-T cell therapy: Updated effectiveness and safety results from real-world evidence                                                                                                                                                           | published  | 166             | 2025 | <a href="https://eprints.aihta.at/1562/">https://eprints.aihta.at/1562/</a> |
| Digital health technologies for self-identification of the risk of perinatal mental illness                                                                                                                                                     | published  | 167             | 2025 | <a href="https://eprints.aihta.at/1571/">https://eprints.aihta.at/1571/</a> |
| Nudges to Optimise Prescriber Behaviour of Physicians                                                                                                                                                                                           | published  | 168             | 2025 | <a href="https://eprints.aihta.at/1593/">https://eprints.aihta.at/1593/</a> |
| Systematic Review of the Long-Term Effectiveness and Safety of Enzyme Replacement Therapy in Mucopolysaccharidoses Disorders and Pompe Disease                                                                                                  | ongoing    | 169             | 2025 | <a href="https://eprints.aihta.at/1599/">https://eprints.aihta.at/1599/</a> |
| Further Development of the Program on Preventiv: Brief interventions for lifestyle counselling: Umbrella review and qualitative surveye Medical Check-Ups in Austria                                                                            | published  | 170a            | 2025 | <a href="https://eprints.aihta.at/1576/">https://eprints.aihta.at/1576/</a> |
| Further Development of the Programme on Preventive Health Check-Ups: Risk Scores for Cardiovascular Disease: A Systematic Review                                                                                                                | published  | 170b            | 2025 | <a href="https://eprints.aihta.at/1577/">https://eprints.aihta.at/1577/</a> |
| Further Development of the Program on Preventive Health Check-Ups: Screening for Chronic Kidney Disease - a rapid review on benefits, harms and target populations                                                                              | published  | 170c            | 2025 | <a href="https://eprints.aihta.at/1573/">https://eprints.aihta.at/1573/</a> |
| Artificial Intelligence for Hospital Documentation Support - A Scoping Review of Current Use Cases                                                                                                                                              | published  | 171a            | 2026 | <a href="https://eprints.aihta.at/1597/">https://eprints.aihta.at/1597/</a> |

| Title                                                                                                                                                             | Status    | No.               | Year | Download/Link                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------------------|------|-----------------------------------------------------------------------------|
| AI-supported Chest X-Ray Analysis for Lung Cancer Detection - Systematic Review of clinical outcomes and organisational implications                              | published | 171b              | 2026 | <a href="https://eprints.aihta.at/1598/">https://eprints.aihta.at/1598/</a> |
| Telekardiologie bei Herzinsuffizienz: Evidenzbewertung und Evaluationskonzept für telemedizinisch unterstützte Versorgungsprogramme in Österreich                 | published | 172               | 2025 | <a href="https://eprints.aihta.at/1594/">https://eprints.aihta.at/1594/</a> |
| Social Prescribing in Primary Care - Development of an Austrian programme theory based on realist evidence                                                        | published | 173               | 2025 | <a href="https://eprints.aihta.at/1581/">https://eprints.aihta.at/1581/</a> |
| Health Economic Reference Cases and Costing Approaches – Concepts, International Practices and Implications for Austria                                           | published | 174               | 2026 | <a href="https://eprints.aihta.at/1601/">https://eprints.aihta.at/1601/</a> |
| Structured Medication Review for Polypharmacy – Systematic Review                                                                                                 | published | 175               | 2026 | <a href="https://eprints.aihta.at/1600/">https://eprints.aihta.at/1600/</a> |
| Genetische Untersuchungen in Österreich. Teil A: Anwendungsgebiete, internationale Erstattungsprozesse und Priorisierungskriterien                                | published | 176a              | 2026 | <a href="https://eprints.aihta.at/1602/">https://eprints.aihta.at/1602/</a> |
| Genetic Testing in Austria. Part B: Carrier Screening for Selected Genetic Conditions                                                                             | published | 176b              | 2026 | <a href="https://eprints.aihta.at/1603/">https://eprints.aihta.at/1603/</a> |
| Genetic Testing in Austria. Part C: Detection of PIK3CA/AKT1/PTEN/ESR1 genetic alterations in HR+/HER2– breast cancer                                             | published | 176c              | 2026 | <a href="https://eprints.aihta.at/1604/">https://eprints.aihta.at/1604/</a> |
| Transition from Child and Adolescent to Adult Mental Health Services: Analysis and Comparison of International Models                                             | published | 177               | 2025 | <a href="https://eprints.aihta.at/1574/">https://eprints.aihta.at/1574/</a> |
| Music therapy: Clinical and socioeconomic outcomes and long-term measures in substance use disorder                                                               | published | 178               | 2026 | <a href="https://eprints.aihta.at/1607/">https://eprints.aihta.at/1607/</a> |
| Guidance for Searching and Finding Public contributions to pharmaceutical R&D                                                                                     | published | 179               | 2026 | <a href="https://eprints.aihta.at/1595/">https://eprints.aihta.at/1595/</a> |
| Health navigators                                                                                                                                                 | published | 180               | 2026 | <a href="https://eprints.aihta.at/1613/">https://eprints.aihta.at/1613/</a> |
| Preparatory work for Austrian health economic guidelines – review of processes (development, dissemination, implementation, monitoring)                           | ongoing   | 181a              |      |                                                                             |
| Overview of National Health Economic Evaluation Guidelines: International Best Practices and Implications for Austria                                             | published | 181b              | 2026 | <a href="https://eprints.aihta.at/1606/">https://eprints.aihta.at/1606/</a> |
| Combination Therapy with Antidepressants and Vitamin B Complex Compared to Antidepressant Monotherapy – a Systematic Review                                       | published | 182               | 2026 | <a href="https://eprints.aihta.at/1605/">https://eprints.aihta.at/1605/</a> |
| Effectiveness of health warning labels on alcoholic beverages: A systematic review with a narrative analysis for Austria                                          | ongoing   | 183               |      |                                                                             |
| <b>Rapid Assessments</b>                                                                                                                                          |           |                   |      |                                                                             |
| Drug eluting stents in comparison to uncoated stents in the treatment of cardiopathy                                                                              | published | 1                 | 2006 | <a href="http://eprints.aihta.at/34/">http://eprints.aihta.at/34/</a>       |
| Avastin® for age-related macular degeneration                                                                                                                     | published | 2                 | 2007 | <a href="http://eprints.aihta.at/718/">http://eprints.aihta.at/718/</a>     |
| Rational Vaccination Policies - decision support. Review of International Literature for "Rational" Vaccination Policies                                          | published | 3                 | 2008 | <a href="http://eprints.aihta.at/761/">http://eprints.aihta.at/761/</a>     |
| Sacral Nerve Stimulation for Fecal Incontinence                                                                                                                   | published | 4                 | 2011 | <a href="http://eprints.aihta.at/925/">http://eprints.aihta.at/925/</a>     |
| Avastin® for age-related macular degeneration: Gutachten zu Stand des Wissens                                                                                     | published | 5                 | 2012 | <a href="http://eprints.aihta.at/989/">http://eprints.aihta.at/989/</a>     |
| Hybrid-Operation rooms                                                                                                                                            | published | 6                 | 2013 | <a href="http://eprints.aihta.at/995/">http://eprints.aihta.at/995/</a>     |
| Transparency: continuing medical education and NIS database                                                                                                       | published | 7a                | 2015 | <a href="http://eprints.aihta.at/1053/">http://eprints.aihta.at/1053/</a>   |
| Transparency: continuing medical education                                                                                                                        | published | 7b                | 2015 | <a href="http://eprints.aihta.at/1072/">http://eprints.aihta.at/1072/</a>   |
| Transparency: continuing medical education/observational study and NIS database                                                                                   | published | 7c                | 2016 | <a href="http://eprints.aihta.at/1080/">http://eprints.aihta.at/1080/</a>   |
| Pharma: Disclosure of transfers of value in austria 2015                                                                                                          | published | 7d                | 2017 | <a href="http://eprints.aihta.at/1107/">http://eprints.aihta.at/1107/</a>   |
| Drugs in Oncology: an overview of benefit and refund practices in Europe                                                                                          | published | 8                 | 2016 | <a href="http://eprints.aihta.at/1091/">http://eprints.aihta.at/1091/</a>   |
| HTAs on Medical Devices and Procedures in Europe: Timing, Risk-Classes, Product-Groups, Assessments                                                               | published | 12                | 2016 | <a href="http://eprints.aihta.at/1108/">http://eprints.aihta.at/1108/</a>   |
| Importance and transparency of non-interventional drug studies (NIS) in selected countries: A comparison with Austria                                             | published | 7c/1. Update 2017 | 2017 | <a href="http://eprints.aihta.at/1122/">http://eprints.aihta.at/1122/</a>   |
| Sponsoring of Patient Initiatives in Austria 2015. Update of the Systematic Analysis 2014                                                                         | published | 7b/1. Update 2017 | 2017 | <a href="http://eprints.aihta.at/1125/">http://eprints.aihta.at/1125/</a>   |
| Sponsoring of Patient Initiatives in Austria 2016. Update of the Systematic Analysis 2015 and 2014                                                                | published | 7b/2. Update 2017 | 2017 | <a href="http://eprints.aihta.at/1132/">http://eprints.aihta.at/1132/</a>   |
| MammaPrint® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer. EunetHTA report | published | 13                | 2018 | <a href="http://eprints.aihta.at/1147/">http://eprints.aihta.at/1147/</a>   |
| FoundationOne®CDx: Bestimmung von genetischen Profilen solider Tumore                                                                                             | published | 14                | 2019 | <a href="http://eprints.aihta.at/1215/">http://eprints.aihta.at/1215/</a>   |
| Sponsoring of Patient Initiatives in Austria 2018. Update of the Systematic Analyses 2014, 2015 and 2016                                                          | published | 7b/3. Update 2017 | 2019 | <a href="http://eprints.aihta.at/1217/">http://eprints.aihta.at/1217/</a>   |
| Pharma: Disclosure of transfers of value in austria 2018. Update of the systematic analysis 2015                                                                  | published | 7d/1. Update 2019 | 2019 | <a href="http://eprints.aihta.at/1218/">http://eprints.aihta.at/1218/</a>   |
| <b>Policy Briefs</b>                                                                                                                                              |           |                   |      |                                                                             |
| Update 12 Monate Nachbeobachtung: Nusinersen bei Spinaler Muskelatrophie („late onset“) bei Kindern und Jugendlichen ≥ 6 Jahre                                    | published | 1                 | 2020 | <a href="http://eprints.aihta.at/1228/">http://eprints.aihta.at/1228/</a>   |
| Covid-19: HSS/ Horizon Scanning Living Document (Part 1 & Part 2)                                                                                                 | published | 2                 | 2020 | <a href="http://eprints.aihta.at/1234/">http://eprints.aihta.at/1234/</a>   |
| PET-Indikations                                                                                                                                                   | published | 3                 | 2020 | <a href="http://eprints.aihta.at/1249/">http://eprints.aihta.at/1249/</a>   |
| Update: Proton- and Carbon Ion therapy                                                                                                                            | published | 4                 | 2020 | <a href="http://eprints.aihta.at/1245/">http://eprints.aihta.at/1245/</a>   |
| Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence – recommendations from evidence-based guidelines                 | published | 5                 | 2021 | <a href="http://eprints.aihta.at/1303/">http://eprints.aihta.at/1303/</a>   |
| Car-T Cell Therapies                                                                                                                                              | published | 6a                | 2020 | <a href="http://eprints.aihta.at/1268/">http://eprints.aihta.at/1268/</a>   |
| ATMPs and Gene Therapies                                                                                                                                          | published | 6b                | 2020 | <a href="http://eprints.aihta.at/1269/">http://eprints.aihta.at/1269/</a>   |
| Transparency: Sponsoring of patient initiatives, Update                                                                                                           | published | 7                 | 2021 | <a href="https://eprints.aihta.at/1308/">https://eprints.aihta.at/1308/</a> |
| Combinationtherapy Casirivimab plus Imdevimab (REGN-COV2) for the treatment of covid-19                                                                           | published | 8                 | 2021 | <a href="http://eprints.aihta.at/1313/">http://eprints.aihta.at/1313/</a>   |
| Bamlanivimab monotherapy and as combination therapy (with etesevimab) for Covid-19                                                                                | published | 9                 | 2021 | <a href="http://eprints.aihta.at/1314/">http://eprints.aihta.at/1314/</a>   |
| Nicht-Interventionelle Studien (NIS) in Österreich                                                                                                                | published | 10                | 2021 | <a href="https://eprints.aihta.at/1333/">https://eprints.aihta.at/1333/</a> |
| Stool DNA testing for colorectal cancer (CRC) screening                                                                                                           | published | 11                | 2021 | <a href="https://eprints.aihta.at/1335/">https://eprints.aihta.at/1335/</a> |
| ≥ 12 Month Follow-Up of Patients with Spinal Muscular Atrophy (SMA) treated with Spinraza®, Zolgensma® or Combination Therapies                                   | published | 1/1. Update 2021  | 2021 | <a href="https://eprints.aihta.at/1352/">https://eprints.aihta.at/1352/</a> |
| Regulation and financing of prenatal screening and diagnostic examinations for fetal anomalies in selected European countries                                     | published | 12                | 2022 | <a href="https://eprints.aihta.at/1369/">https://eprints.aihta.at/1369/</a> |

| Title                                                                                                                                                                                                                    | Status    | No.             | Year | Download/Link                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------|------|-----------------------------------------------------------------------------|
| Car-T Cell Therapies                                                                                                                                                                                                     | published | 6a/Update 2022  | 2022 | <a href="https://eprints.aihta.at/1368/">https://eprints.aihta.at/1368/</a> |
| ATMPs and Gene Therapies in Development. Horizon Scanning – Update 2022                                                                                                                                                  | published | 6b/ update 2022 | 2022 | <a href="https://eprints.aihta.at/1383">https://eprints.aihta.at/1383</a>   |
| Update PET/PET-CT: Evidenz zum Bedarf und zur Planung bei onkologischen Indikationen, Update 2023                                                                                                                        | published | 3/Update 2023   | 2023 | <a href="https://eprints.aihta.at/1442/">https://eprints.aihta.at/1442/</a> |
| Sponsoring of patient initiatives in Austria. 5th Update of the Systematic Analyses 2014 to 2019. AIHTA Policy Brief 007/ 5. Update.                                                                                     | published | 7/Update 2023   | 2023 | <a href="https://eprints.aihta.at/1443/">https://eprints.aihta.at/1443/</a> |
| SMA-Therapien: Mittel- bis längerfristige Nachbeobachtung von SMA-Patient*innen, behandelt für >=24 Monate mit Nusinersen oder Onasemnogene Apeparovvec, und für >=12 Monate mit Risdiplam (Mono-/Kombinationstherapien) | published | 1. 2. Update    | 2023 | <a href="https://eprints.aihta.at/1485/">https://eprints.aihta.at/1485/</a> |
| Assessment of study report: The Improve Drug Therapy Trial                                                                                                                                                               | ongoing   | 13              |      |                                                                             |
| <b>Decision Support Document for the Austrian Appraisal Board</b>                                                                                                                                                        |           |                 |      |                                                                             |
| Exagamglogene autotemcel (Exa-cel, Casgevy®) zur Behandlung von Beta-Thalassämie und schwerer Sichelzellerkrankheit                                                                                                      | published | 1               | 2025 | <a href="https://eprints.aihta.at/1548/">https://eprints.aihta.at/1548/</a> |
| Fidanacogene elaparovvec (BEQVEZ®) for the treatment of moderate and severe haemophilia B                                                                                                                                | published | 2               | 2025 | <a href="https://eprints.aihta.at/1558/">https://eprints.aihta.at/1558/</a> |
| Exagamglogene autotemcel (Exa-cel, Casgevy®) for the treatment of beta-thalassemia and severe sickle cell disease                                                                                                        | published | 3               | 2025 | <a href="https://eprints.aihta.at/1560/">https://eprints.aihta.at/1560/</a> |
| Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma                                                                                                                                         | published | 4               | 2025 | <a href="https://eprints.aihta.at/1570/">https://eprints.aihta.at/1570/</a> |
| Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia                                                                       | published | 5               | 2025 | <a href="https://eprints.aihta.at/1589/">https://eprints.aihta.at/1589/</a> |
| Dorocubiceel + unexpanded CD34+ cells (Zemcelpro®) for the treatment of haematological malignancies in adults                                                                                                            | published | 6               | 2026 | <a href="https://eprints.aihta.at/1596/">https://eprints.aihta.at/1596/</a> |
| Teplizumab (TEIZEILD®) for stage 2 type 1 diabetes                                                                                                                                                                       | published | 7               | 2026 | <a href="https://eprints.aihta.at/1612/">https://eprints.aihta.at/1612/</a> |
| Tisotumab vedotin (TIVDAK®) for the treatment of adult patients with recurrent or metastatic cervical cancer                                                                                                             | published | 8               | 2026 | <a href="https://eprints.aihta.at/1611/">https://eprints.aihta.at/1611/</a> |
| <b>Decision Support Documents</b>                                                                                                                                                                                        |           |                 |      |                                                                             |
| Photoselective vaporisation of the prostate in men with benign prostatic hyperplasia                                                                                                                                     | published | 1               | 2007 | <a href="http://eprints.aihta.at/747/">http://eprints.aihta.at/747/</a>     |
| Targeted radionuclide therapy with 90Y- and 177-Lu-DOTATOC in patients with neuroendocrine tumors                                                                                                                        | published | 2               | 2007 | <a href="http://eprints.aihta.at/749/">http://eprints.aihta.at/749/</a>     |
| Photodynamic therapy for the treatment of malignant stenosis in the alimentary tract                                                                                                                                     | published | 3               | 2007 | <a href="http://eprints.aihta.at/51/">http://eprints.aihta.at/51/</a>       |
| New minimally invasive methods in the treatment of stress urinary incontinence. Systematic review                                                                                                                        | published | 6               | 2008 | <a href="http://eprints.aihta.at/763/">http://eprints.aihta.at/763/</a>     |
| LDL apheresis. Systematic review                                                                                                                                                                                         | published | 7               | 2008 | <a href="http://eprints.aihta.at/764/">http://eprints.aihta.at/764/</a>     |
| Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review                                                                                                                       | published | 8               | 2008 | <a href="http://eprints.aihta.at/770/">http://eprints.aihta.at/770/</a>     |
| Percutaneous pulmonary valve implantation for right ventricular outflow tract dysfunction in patients with congenital heart defects. Systematic review                                                                   | published | 10              | 2008 | <a href="http://eprints.aihta.at/768/">http://eprints.aihta.at/768/</a>     |
| Selective Cell Apheresis in Inflammatory Bowel Disease                                                                                                                                                                   | published | 11              | 2008 | <a href="http://eprints.aihta.at/792/">http://eprints.aihta.at/792/</a>     |
| Rheopheresis in patients with age-related macular degeneration, sudden hearing loss or tinnitus, diabetes. Systematic review                                                                                             | published | 12              | 2008 | <a href="http://eprints.aihta.at/758/">http://eprints.aihta.at/758/</a>     |
| Optical Coherence Tomography. Systematic review                                                                                                                                                                          | published | 13              | 2008 | <a href="http://eprints.aihta.at/84/">http://eprints.aihta.at/84/</a>       |
| Stent-grafting of the ascending aorta. Systematic review                                                                                                                                                                 | published | 14              | 2008 | <a href="http://eprints.aihta.at/762/">http://eprints.aihta.at/762/</a>     |
| Cardiac contractility modulation for heart failure. Systematic review                                                                                                                                                    | published | 15              | 2008 | <a href="http://eprints.aihta.at/769/">http://eprints.aihta.at/769/</a>     |
| Aromatherapy for pain relief and psychological problems. Systematic review                                                                                                                                               | published | 16              | 2008 | <a href="http://eprints.aihta.at/765/">http://eprints.aihta.at/765/</a>     |
| Bach Flower Remedies for pain relief and psychological problems. Systematic review                                                                                                                                       | published | 17              | 2008 | <a href="http://eprints.aihta.at/767/">http://eprints.aihta.at/767/</a>     |
| Percutaneous aortic valve replacement. Systematic review                                                                                                                                                                 | published | 18              | 2008 | <a href="http://eprints.aihta.at/766/">http://eprints.aihta.at/766/</a>     |
| Enzyme Replacement Therapy for Lysosomal Storage Diseases                                                                                                                                                                | published | 19              | 2008 | <a href="http://eprints.aihta.at/812/">http://eprints.aihta.at/812/</a>     |
| Endobronchial valve implantation for emphysema                                                                                                                                                                           | finished  | 20              | 2008 | not published                                                               |
| Chemonucleolysis and intradiscal electrotherapy (IDET). Systematic Review.                                                                                                                                               | published | 21a             | 2009 | <a href="http://eprints.aihta.at/828/">http://eprints.aihta.at/828/</a>     |
| Percutaneous nucleotomy and percutaneous laser disk decompression. Systematic Review.                                                                                                                                    | published | 21b             | 2009 | <a href="http://eprints.aihta.at/830/">http://eprints.aihta.at/830/</a>     |
| Injection therapies and radiofrequency for the treatment of chronic back pain. Systematic Review.                                                                                                                        | published | 22              | 2009 | <a href="http://eprints.aihta.at/831/">http://eprints.aihta.at/831/</a>     |
| Intraoperative radiotherapy for primary breast cancer. Systematic Review.                                                                                                                                                | published | 23              | 2009 | <a href="http://eprints.aihta.at/832/">http://eprints.aihta.at/832/</a>     |
| Drug coated balloon catheter. Systematic Review.                                                                                                                                                                         | published | 24              | 2009 | <a href="http://eprints.aihta.at/833/">http://eprints.aihta.at/833/</a>     |
| Selective IgG Apheresis for ABO-incompatible kidney transplantation. Systematic Review.                                                                                                                                  | published | 25              | 2009 | <a href="http://eprints.aihta.at/834/">http://eprints.aihta.at/834/</a>     |
| Image guided radiotherapy using cone-beam computed tomography. Systematic Review.                                                                                                                                        | published | 26              | 2009 | <a href="http://eprints.aihta.at/835/">http://eprints.aihta.at/835/</a>     |
| Pumpless extracorporeal lung assist (PECLA). Systematic Review.                                                                                                                                                          | published | 27              | 2009 | <a href="http://eprints.aihta.at/836/">http://eprints.aihta.at/836/</a>     |
| Retroluminal transobturatoric reposition sling for the treatment of stress urinary incontinence in men. Systematic Review.                                                                                               | published | 30              | 2009 | <a href="http://eprints.aihta.at/837/">http://eprints.aihta.at/837/</a>     |
| Stent-grafting of the ascending aorta. Systematic review                                                                                                                                                                 | published | 14/ Update 2009 | 2009 | <a href="http://eprints.aihta.at/895/">http://eprints.aihta.at/895/</a>     |
| Cardiac contractility modulation for heart failure. Systematic review                                                                                                                                                    | published | 15/ Update 2009 | 2009 | <a href="http://eprints.aihta.at/896/">http://eprints.aihta.at/896/</a>     |
| Percutaneous aortic valve replacement. Systematic review                                                                                                                                                                 | published | 18/ Update 2009 | 2009 | <a href="http://eprints.aihta.at/897/">http://eprints.aihta.at/897/</a>     |
| Endobronchial valve implantation for emphysema. Systematic review                                                                                                                                                        | finished  | 20/ Update 2009 | 2009 | not published                                                               |
| Bioresonance for allergies, atopic dermatitis, non-organic gastrointestinal complaints, pain and rheumatic diseases.                                                                                                     | published | 31              | 2009 | <a href="http://eprints.aihta.at/842/">http://eprints.aihta.at/842/</a>     |
| Colon Hydrotherapy for defecation disorders. Systematic Review                                                                                                                                                           | published | 32              | 2009 | <a href="http://eprints.aihta.at/827/">http://eprints.aihta.at/827/</a>     |
| International comparison of antenatal care in pregnant women                                                                                                                                                             | published | 33              | 2009 | <a href="http://eprints.aihta.at/826/">http://eprints.aihta.at/826/</a>     |
| Autologous Chondrocyte Implantation                                                                                                                                                                                      | published | 34              | 2009 | <a href="http://eprints.aihta.at/865/">http://eprints.aihta.at/865/</a>     |

| Title                                                                                                                                              | Status    | No.             | Year | Download/Link                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----------------|------|---------------------------------------------------------------------------|
| New influenza (swine flu) – data & facts for decision support.                                                                                     | published | 35              | 2009 | <a href="http://eprints.aihta.at/845/">http://eprints.aihta.at/845/</a>   |
| Hyperthermia                                                                                                                                       | published | 36              | 2010 | <a href="http://eprints.aihta.at/883/">http://eprints.aihta.at/883/</a>   |
| High intensity focused ultrasound (HIFU) for the treatment of prostate cancer                                                                      | published | 37              | 2010 | <a href="http://eprints.aihta.at/887/">http://eprints.aihta.at/887/</a>   |
| Artificial disc replacement                                                                                                                        | published | 38              | 2010 | <a href="http://eprints.aihta.at/886/">http://eprints.aihta.at/886/</a>   |
| Laser angioplasty of coronary arteries                                                                                                             | published | 39              | 2010 | <a href="http://eprints.aihta.at/885/">http://eprints.aihta.at/885/</a>   |
| Radionuclide therapy - 90Yttrium and 177Lutetium somatostatin analogues for the treatment of inoperable neuroendocrine tumors                      | published | 40              | 2010 | <a href="http://eprints.aihta.at/889/">http://eprints.aihta.at/889/</a>   |
| Mitral valve repair using a mitral clip                                                                                                            | published | 41              | 2010 | <a href="http://eprints.aihta.at/888/">http://eprints.aihta.at/888/</a>   |
| Kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures. Systematic review                                                 | published | 8/ Update 2010  | 2010 | <a href="http://eprints.aihta.at/890/">http://eprints.aihta.at/890/</a>   |
| Stent-grafting of the ascending aorta. Systematic review                                                                                           | published | 14/ Update 2010 | 2010 | <a href="http://eprints.aihta.at/892/">http://eprints.aihta.at/892/</a>   |
| Cardiac contractility modulation for heart failure. Systematic review                                                                              | published | 15/ Update 2010 | 2010 | <a href="http://eprints.aihta.at/893/">http://eprints.aihta.at/893/</a>   |
| Percutaneous aortic valve replacement. Systematic review                                                                                           | published | 18/ Update 2010 | 2010 | <a href="http://eprints.aihta.at/894/">http://eprints.aihta.at/894/</a>   |
| Endobronchial valve implantation for emphysema. Systematic review                                                                                  | published | 20/ Update 2010 | 2010 | <a href="http://eprints.aihta.at/891/">http://eprints.aihta.at/891/</a>   |
| Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. German version.                                   | published | 43              | 2011 | <a href="http://eprints.aihta.at/916/">http://eprints.aihta.at/916/</a>   |
| Anti-Vascular-Endothelial-Growth-Factor (anti-VEGF) for the treatment of diabetic macular edema. English version.                                  | published | 43              | 2011 | <a href="http://eprints.aihta.at/917/">http://eprints.aihta.at/917/</a>   |
| Percutaneous Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation                       | published | 44              | 2011 | <a href="http://eprints.aihta.at/918/">http://eprints.aihta.at/918/</a>   |
| Renal denervation in patients with essential hypertension                                                                                          | published | 45              | 2011 | <a href="http://eprints.aihta.at/919/">http://eprints.aihta.at/919/</a>   |
| Mechanical percutaneous transluminal cerebral clot retrieval in acute ischemic stroke                                                              | published | 46              | 2011 | <a href="http://eprints.aihta.at/920/">http://eprints.aihta.at/920/</a>   |
| Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. German version.  | published | 47              | 2011 | <a href="http://eprints.aihta.at/921/">http://eprints.aihta.at/921/</a>   |
| Selective internal radiation therapy using yttrium-90 microspheres for the treatment of primary or metastatic liver malignancies. English version. | published | 47              | 2011 | <a href="http://eprints.aihta.at/922/">http://eprints.aihta.at/922/</a>   |
| Percutaneous aortic valve replacement with a side note to hybrid operating rooms                                                                   | published | 18/ Update 2011 | 2011 | <a href="http://eprints.aihta.at/923/">http://eprints.aihta.at/923/</a>   |
| Outpatient cardiac rehabilitation. Part 4: Options for carrying out a prospective study                                                            | published | 48              | 2011 | <a href="http://eprints.aihta.at/928/">http://eprints.aihta.at/928/</a>   |
| Radiofrequency ablation for hepatocellular carcinoma and colorectal liver metastases                                                               | published | 49              | 2011 | <a href="http://eprints.aihta.at/933/">http://eprints.aihta.at/933/</a>   |
| Outpatient cardiac rehabilitation Part 5: Preparation of the study protocol for the planned prospective study                                      | published | 50              | 2012 | <a href="http://eprints.aihta.at/971/">http://eprints.aihta.at/971/</a>   |
| Training therapy in physical medicine – Systematic Review                                                                                          | published | 51              | 2012 | <a href="http://eprints.aihta.at/950/">http://eprints.aihta.at/950/</a>   |
| Exercise therapy (Kränkengymnastik/ Heilgymnastik) in physical medicine                                                                            | published | 52              | 2012 | <a href="http://eprints.aihta.at/951/">http://eprints.aihta.at/951/</a>   |
| Radiofrequency ablation of tumors of the lung and mediastinal lymph nodes                                                                          | published | 53              | 2012 | <a href="http://eprints.aihta.at/957/">http://eprints.aihta.at/957/</a>   |
| Radiofrequency ablation of bone tumors (osteoid-osteoma and osseous metastases)                                                                    | published | 54              | 2012 | <a href="http://eprints.aihta.at/958/">http://eprints.aihta.at/958/</a>   |
| Radiofrequency ablation of head and neck cancer                                                                                                    | published | 55              | 2012 | <a href="http://eprints.aihta.at/959/">http://eprints.aihta.at/959/</a>   |
| Radiofrequency ablation of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland)                                         | published | 56              | 2012 | <a href="http://eprints.aihta.at/960/">http://eprints.aihta.at/960/</a>   |
| Radiofrequency ablation of breast cancer                                                                                                           | published | 57              | 2012 | <a href="http://eprints.aihta.at/961/">http://eprints.aihta.at/961/</a>   |
| Radiofrequency ablation of primary tumors of the gastrointestinal tract (colorectal and pancreatic cancer)                                         | published | 58              | 2012 | <a href="http://eprints.aihta.at/962/">http://eprints.aihta.at/962/</a>   |
| Radiofrequency ablation of tumors of the urogenital tract (renal cell carcinoma, prostate cancer, uterine leiomyoma)                               | published | 59              | 2012 | <a href="http://eprints.aihta.at/963/">http://eprints.aihta.at/963/</a>   |
| Sling suspension in male urinary incontinence                                                                                                      | published | 60              | 2012 | <a href="http://eprints.aihta.at/964/">http://eprints.aihta.at/964/</a>   |
| Stem cell therapy for urinary stress incontinence                                                                                                  | published | 6/Update 2012   | 2012 | <a href="http://eprints.aihta.at/965/">http://eprints.aihta.at/965/</a>   |
| Mitral valve repair using a mitral clip                                                                                                            | published | 41/Update 2012  | 2012 | <a href="http://eprints.aihta.at/967/">http://eprints.aihta.at/967/</a>   |
| Intraoperative radiotherapy for primary breast cancer. Systematic Review.                                                                          | published | 23/Update 2012  | 2012 | <a href="http://eprints.aihta.at/966/">http://eprints.aihta.at/966/</a>   |
| Renal denervation in patients with essential hypertension                                                                                          | published | 45/update 2012  | 2012 | <a href="http://eprints.aihta.at/968/">http://eprints.aihta.at/968/</a>   |
| HIV testing in healthy subjects: an international comparison Austria                                                                               | published | 61              | 2012 | <a href="http://eprints.aihta.at/979/">http://eprints.aihta.at/979/</a>   |
| Extracorporeal shock wave therapy (ESWT) of non-union or delayed union of fractures                                                                | published | 62              | 2012 | <a href="http://eprints.aihta.at/975/">http://eprints.aihta.at/975/</a>   |
| Hyperthermia                                                                                                                                       | published | 36/Update 2012  | 2012 | <a href="http://eprints.aihta.at/986/">http://eprints.aihta.at/986/</a>   |
| Evidence overview of therapeutic hypothermia                                                                                                       | published | 63              | 2012 | <a href="http://eprints.aihta.at/985/">http://eprints.aihta.at/985/</a>   |
| Percutaneous coronary intervention for chronic total occlusion                                                                                     | published | 64              | 2013 | <a href="http://eprints.aihta.at/1000/">http://eprints.aihta.at/1000/</a> |
| Implantation of a lumbar artificial endoprosthesis (anuloplasty/ anular repair device)                                                             | published | 65              | 2013 | <a href="http://eprints.aihta.at/1001/">http://eprints.aihta.at/1001/</a> |
| Repair of cartilage defects via matrix-associated autologous chondrocyte immigration                                                               | published | 66              | 2013 | <a href="http://eprints.aihta.at/1002/">http://eprints.aihta.at/1002/</a> |
| Duodeno-jejunal bypass liner (DJBL) for patients with obesity                                                                                      | published | 67              | 2013 | <a href="http://eprints.aihta.at/1008/">http://eprints.aihta.at/1008/</a> |
| Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB)                                                  | published | 68              | 2013 | <a href="http://eprints.aihta.at/1003/">http://eprints.aihta.at/1003/</a> |
| Endovascular repair of aortic aneurysms                                                                                                            | published | 69              | 2013 | <a href="http://eprints.aihta.at/1004/">http://eprints.aihta.at/1004/</a> |
| Percutaneous transcatheter closure of prosthetic mitral and aortic paravalvular leaks                                                              | published | 70              | 2013 | <a href="http://eprints.aihta.at/1005/">http://eprints.aihta.at/1005/</a> |
| Percutaneous transluminal septal myocardial ablation (PTSMA) in hypertrophic obstructive cardiomyopathy (HOCM)                                     | published | 71              | 2013 | <a href="http://eprints.aihta.at/1006/">http://eprints.aihta.at/1006/</a> |
| Percutaneous transluminal coronary angioplasty (PTCA) with paclitaxel-coated drug-eluting balloon (DEB) (1st Update)                               | published | 24/Update 2013  | 2013 | <a href="http://eprints.aihta.at/1007/">http://eprints.aihta.at/1007/</a> |
| Assessment – APPRAISAL – Decision: (Good) Practice examples and recommendations                                                                    | published | 72              | 2014 | <a href="http://eprints.aihta.at/1036/">http://eprints.aihta.at/1036/</a> |

| Title                                                                                                                                                                    | Status    | No.               | Year | Download/Link                                                             |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-------------------|------|---------------------------------------------------------------------------|
| Zostavax® for prevention of Herpes Zoster                                                                                                                                | published | 73                | 2013 | <a href="http://eprints.aihta.at/1013/">http://eprints.aihta.at/1013/</a> |
| Hyperthermic intraperitoneal chemotherapy (HIPEC) for treatment of peritoneal carcinosis                                                                                 | published | 74                | 2014 | <a href="http://eprints.aihta.at/1031/">http://eprints.aihta.at/1031/</a> |
| Percutaneous transluminal angioplasty (PTA) with drug-eluting stents                                                                                                     | published | 75                | 2014 | <a href="http://eprints.aihta.at/1032/">http://eprints.aihta.at/1032/</a> |
| Endobronchial valves in emphysema                                                                                                                                        | published | 20/Update 2014    | 2014 | <a href="http://eprints.aihta.at/1028/">http://eprints.aihta.at/1028/</a> |
| Percutaneous left atrial appendage closure                                                                                                                               | published | 44/Update 2014    | 2014 | <a href="http://eprints.aihta.at/1029/">http://eprints.aihta.at/1029/</a> |
| Stereotactic Radiofrequency Ablation (SRFA) in hepatocellular carcinoma                                                                                                  | published | 76                | 2014 | <a href="http://eprints.aihta.at/1030/">http://eprints.aihta.at/1030/</a> |
| Biomarker guidance                                                                                                                                                       | published | 77                | 2014 | <a href="http://eprints.aihta.at/1041/">http://eprints.aihta.at/1041/</a> |
| Re-orientation of the Austrian parent-child preventive care programme Part 10: further development of the mother-child-pass. Scientific support of the appraisal process | published | 78                | 2014 | <a href="http://eprints.aihta.at/1039/">http://eprints.aihta.at/1039/</a> |
| Vaccination against Human Papillomavirus (HPV). Decision Support for adolescent girls and women/ mothers                                                                 | finished  | 79                | 2014 | not published                                                             |
| Outpatient cardiac rehabilitation. Part 6a: Multi-centre, prospective cohort study with two control groups (with/without phase III). Baseline characteristics.           | finished  | 80                | 2014 | not published                                                             |
| Fully bioresorbable scaffolds for coronary artery disease: Systematic Review                                                                                             | published | 81                | 2015 | <a href="http://eprints.aihta.at/1060/">http://eprints.aihta.at/1060/</a> |
| Transcatheter mitral valve-in-valve implantation (TMViV)                                                                                                                 | published | 82                | 2015 | <a href="http://eprints.aihta.at/1058/">http://eprints.aihta.at/1058/</a> |
| Endovascular embolisation of intracranial aneurysms with Flow Diverter                                                                                                   | published | 83                | 2015 | <a href="http://eprints.aihta.at/1054/">http://eprints.aihta.at/1054/</a> |
| Defibrotide for hepatic veno-occlusive disease                                                                                                                           | published | 84                | 2015 | <a href="http://eprints.aihta.at/1061/">http://eprints.aihta.at/1061/</a> |
| Intracorneal ring segments for keratoconus                                                                                                                               | published | 85                | 2015 | <a href="http://eprints.aihta.at/1055/">http://eprints.aihta.at/1055/</a> |
| Neurostimulation for cluster headache                                                                                                                                    | published | 86                | 2015 | <a href="http://eprints.aihta.at/1062/">http://eprints.aihta.at/1062/</a> |
| Local injection therapy with bulking agents for faecal incontinence                                                                                                      | published | 87                | 2015 | <a href="http://eprints.aihta.at/1059/">http://eprints.aihta.at/1059/</a> |
| Percutaneous left atrial appendage closure (2.Update 2015)                                                                                                               | published | 44/Update 2015    | 2015 | <a href="http://eprints.aihta.at/1056/">http://eprints.aihta.at/1056/</a> |
| Percutaneous transluminal angioplasty (PTA) of periphery arteries with drug-eluting balloon (DEB) (1.Update 2015)                                                        | published | 68/Update 2015    | 2015 | <a href="http://eprints.aihta.at/1057/">http://eprints.aihta.at/1057/</a> |
| Hadron therapy in children. Evidence synthesis to 15 pediatric tumors                                                                                                    | published | 88                | 2015 | <a href="http://eprints.aihta.at/1049/">http://eprints.aihta.at/1049/</a> |
| Biodegradable stents for the treatment of refractory or recurrent benign oesophageal Stenosis: German summary to EUnetHTA-report                                         | published | 89                | 2015 | <a href="http://eprints.aihta.at/1067/">http://eprints.aihta.at/1067/</a> |
| Background Analysis for National HTA Strategy for Lithuania: Focus on Medical Devices                                                                                    | published | 90                | 2015 | <a href="http://eprints.aihta.at/1063/">http://eprints.aihta.at/1063/</a> |
| HTA Strategy for Lithuania                                                                                                                                               | published | 90a               | 2015 | <a href="http://eprints.aihta.at/1064/">http://eprints.aihta.at/1064/</a> |
| Balloon Eustachian Tuboplasty for the treatment of Eustachian tube dysfunction: German summary to EUnetHTA-report                                                        | published | 91                | 2015 | <a href="http://eprints.aihta.at/1073/">http://eprints.aihta.at/1073/</a> |
| Outpatient neurological rehabilitation: goal attainment in stroke patients. Systematic review.                                                                           | published | 92                | 2015 | <a href="http://eprints.aihta.at/1071/">http://eprints.aihta.at/1071/</a> |
| Percutaneous mitral repair with chronic mitral insufficiency (Mitraclip®, Carillon®, NeoChord DS1000) . German Executive summary of the same EUnetHTA report             | published | 93                | 2015 | <a href="http://eprints.aihta.at/1075/">http://eprints.aihta.at/1075/</a> |
| Mechanical thrombectomy in acute ischemic stroke. German Executive summary of the same report EUnetHTA                                                                   | published | 94                | 2016 | <a href="http://eprints.aihta.at/1081/">http://eprints.aihta.at/1081/</a> |
| Screening, diagnostic testing and therapeutic indication for occupational therapy in children and adolescents with Developmental Coordination Disorder                   | published | 96                | 2016 | <a href="http://eprints.aihta.at/1092/">http://eprints.aihta.at/1092/</a> |
| Leadless pacemakers for right ventricle pacing                                                                                                                           | published | 97                | 2016 | <a href="http://eprints.aihta.at/1094/">http://eprints.aihta.at/1094/</a> |
| Autologous matrix-induced chondrogenesis for cartilage repair                                                                                                            | published | 98                | 2016 | <a href="http://eprints.aihta.at/1095/">http://eprints.aihta.at/1095/</a> |
| Radiofrequency denervation for low back pain                                                                                                                             | published | 99                | 2016 | <a href="http://eprints.aihta.at/1096/">http://eprints.aihta.at/1096/</a> |
| Hypoglossal nerve stimulation for obstructive sleep apnoe                                                                                                                | published | 100               | 2016 | <a href="http://eprints.aihta.at/1097/">http://eprints.aihta.at/1097/</a> |
| Magnetic esophageal ring for gastroesophageal reflux disease                                                                                                             | published | 101               | 2016 | <a href="http://eprints.aihta.at/1098/">http://eprints.aihta.at/1098/</a> |
| Percutaneous transluminal coronary angioplasty with drug-eluting balloon                                                                                                 | published | 24/ Update 2016   | 2016 | <a href="http://eprints.aihta.at/1093/">http://eprints.aihta.at/1093/</a> |
| Hepatitis C virus screening in hospitals                                                                                                                                 | published | 102               | 2016 | <a href="http://eprints.aihta.at/1103/">http://eprints.aihta.at/1103/</a> |
| Portable cardioverter defibrillator therapy for primary and secondary prevention of sudden cardiac arrest                                                                | published | 103               | 2016 | <a href="http://eprints.aihta.at/1109/">http://eprints.aihta.at/1109/</a> |
| Electric stimulation therapy (EST) in patients with gastroesophageal reflux disease (GERD)                                                                               | published | 104               | 2017 | <a href="http://eprints.aihta.at/1128/">http://eprints.aihta.at/1128/</a> |
| Prostate artery embolisation for benign prostatic hyperplasia                                                                                                            | published | 105               | 2017 | <a href="http://eprints.aihta.at/1118/">http://eprints.aihta.at/1118/</a> |
| Extracorporeal cytokine haemadsorption in patients with sepsis or SIRS                                                                                                   | published | 106               | 2017 | <a href="http://eprints.aihta.at/1129/">http://eprints.aihta.at/1129/</a> |
| Repetitive transcranial magnetic stimulation for treatment-resistant major depression                                                                                    | published | 107               | 2017 | <a href="http://eprints.aihta.at/1130/">http://eprints.aihta.at/1130/</a> |
| Radiofrequency ablation for metastatic spinal lesions                                                                                                                    | published | 108               | 2017 | <a href="http://eprints.aihta.at/1131/">http://eprints.aihta.at/1131/</a> |
| Percutaneous disc volume reduction with focus on chemonucleolysis                                                                                                        | published | 21 /Update 2017   | 2017 | <a href="http://eprints.aihta.at/1126/">http://eprints.aihta.at/1126/</a> |
| Leadless pacemakers for right ventricle pacing                                                                                                                           | published | 97/Update 2017    | 2017 | <a href="http://eprints.aihta.at/1127/">http://eprints.aihta.at/1127/</a> |
| Endobronchial valve implantation for emphysema                                                                                                                           | published | 20/4.Update 2018  | 2018 | <a href="http://eprints.aihta.at/1166/">http://eprints.aihta.at/1166/</a> |
| High intensity focused ultrasound (HIFU) for the treatment of prostate cancer                                                                                            | published | 37/1. Update 2018 | 2018 | <a href="http://eprints.aihta.at/1167/">http://eprints.aihta.at/1167/</a> |
| Left Atrial Appendage Closure for the prevention of thrombo-embolic events in patients with atrial fibrillation                                                          | published | 44/3. Update 2018 | 2018 | <a href="http://eprints.aihta.at/1168/">http://eprints.aihta.at/1168/</a> |
| Subcutaneous implantable cardioverter defibrillator (ICD)                                                                                                                | published | 109               | 2018 | <a href="http://eprints.aihta.at/1169/">http://eprints.aihta.at/1169/</a> |
| Lymphovenous anastomoses in patients with primary and secondary lymphedema                                                                                               | published | 110               | 2018 | <a href="http://eprints.aihta.at/1170/">http://eprints.aihta.at/1170/</a> |
| Allogeneic mesenchymal stem cells for Crohn's disease-associated complex perianal fistulas                                                                               | published | 111               | 2018 | <a href="http://eprints.aihta.at/1171/">http://eprints.aihta.at/1171/</a> |
| Meniscal allograft transplantation                                                                                                                                       | published | 112               | 2018 | <a href="http://eprints.aihta.at/1172/">http://eprints.aihta.at/1172/</a> |
| Baroreceptor activation therapy for treatment-resistant hypertension                                                                                                     | published | 113               | 2018 | <a href="http://eprints.aihta.at/1173/">http://eprints.aihta.at/1173/</a> |

| Title                                                                                                                                                                                                                     | Status    | No.                | Year | Download/Link                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------|------|-----------------------------------------------------------------------------|
| External stimulation of the trigeminal nerve for the prevention and treatment of episodic and chronic migraine (Cefaly)                                                                                                   | published | 114                | 2018 | <a href="http://eprints.aihta.at/1177/">http://eprints.aihta.at/1177/</a>   |
| Wearable cardioverter-defibrillator (WCD) therapy as prevention of sudden cardiac death in patients at risk - Update 2018                                                                                                 | published | 103/Update 2018    | 2019 | <a href="http://eprints.aihta.at/1186">http://eprints.aihta.at/1186</a>     |
| Osteochondral Allograft Transplantation (knee or other joints)                                                                                                                                                            | published | 115                | 2019 | <a href="http://eprints.aihta.at/1204">http://eprints.aihta.at/1204</a>     |
| Allograft for anterior and posterior cruciate ligament reconstruction                                                                                                                                                     | published | 116                | 2019 | <a href="http://eprints.aihta.at/1205">http://eprints.aihta.at/1205</a>     |
| Human dermal allograft for reconstruction of rotator cuff tears                                                                                                                                                           | published | 117                | 2019 | <a href="http://eprints.aihta.at/1206">http://eprints.aihta.at/1206</a>     |
| Lu-177-labeled Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant metastatic Prostate Cancer                                                                                      | published | 118                | 2019 | <a href="http://eprints.aihta.at/1207">http://eprints.aihta.at/1207</a>     |
| Radiofrequency denervation for lumbar and cervical facet joint pain                                                                                                                                                       | published | 99/Update 2019     | 2019 | <a href="http://eprints.aihta.at/1202">http://eprints.aihta.at/1202</a>     |
| (Single-step) scaffold-based cartilage repair in the knee                                                                                                                                                                 | published | 98/Update 2019     | 2019 | <a href="http://eprints.aihta.at/1201">http://eprints.aihta.at/1201</a>     |
| Implantation of a lumbar artificial endoprosthesis (anuloplasty/ anular repair device)                                                                                                                                    | published | 65/ Update 2019    | 2019 | <a href="http://eprints.aihta.at/1200">http://eprints.aihta.at/1200</a>     |
| Upper airway stimulation for moderate-to-severe sleep apnea                                                                                                                                                               | published | 100/Update 2019    | 2019 | <a href="http://eprints.aihta.at/1203">http://eprints.aihta.at/1203</a>     |
| Bioresorbable stents for the treatment of cardiovascular indications (coronary artery disease). EUnetHTA-Report                                                                                                           | published | 81/1.Update 2019   | 2019 | <a href="http://eprints.aihta.at/1191/">http://eprints.aihta.at/1191/</a>   |
| Telemonitoring and pulmonary artery pressure-guided treatment of heart failure                                                                                                                                            | published | 119                | 2020 | <a href="http://eprints.aihta.at/1254">http://eprints.aihta.at/1254</a>     |
| Ultrasound-guided transcervical Radiofrequency ablation of Myoma                                                                                                                                                          | published | 120                | 2020 | <a href="http://eprints.aihta.at/1255">http://eprints.aihta.at/1255</a>     |
| Leadless Pacemakers for Right Ventricle Pacing                                                                                                                                                                            | published | 97/Update 2019     | 2020 | <a href="http://eprints.aihta.at/1252">http://eprints.aihta.at/1252</a>     |
| Extracorporeal cytokine headsorption                                                                                                                                                                                      | published | 106/Update 2019    | 2020 | <a href="http://eprints.aihta.at/1253">http://eprints.aihta.at/1253</a>     |
| Percutaneous transvascular implantation of a coronary sinus constricting stent                                                                                                                                            | published | 121                | 2020 | <a href="http://eprints.aihta.at/1256">http://eprints.aihta.at/1256</a>     |
| Radiofrequency-Induced Intravesical Chemohyperthermia for Non-Muscle-Invasive Bladder Cancer                                                                                                                              | published | 122                | 2020 | <a href="http://eprints.aihta.at/1258">http://eprints.aihta.at/1258</a>     |
| Photodynamic therapy in prostate cancer with padeliporfin (TOOKAD)                                                                                                                                                        | published | 123                | 2020 | <a href="http://eprints.aihta.at/1258">http://eprints.aihta.at/1258</a>     |
| ercutaneous left ventricular assist devices: micro-axial flow pumps                                                                                                                                                       | published | 124                | 2021 | <a href="https://eprints.aihta.at/1323">https://eprints.aihta.at/1323</a>   |
| Liposuction for surgical therapy of lipoeidema                                                                                                                                                                            | published | 125                | 2021 | <a href="https://eprints.aihta.at/1324">https://eprints.aihta.at/1324</a>   |
| Triphasic biomaterial for augmentation of the osteoporotic femoral neck                                                                                                                                                   | published | 126                | 2021 | <a href="https://eprints.aihta.at/1325">https://eprints.aihta.at/1325</a>   |
| Endoscopic plication therapy in patients with gastroesophageal reflux disease (GERD)                                                                                                                                      | published | 127                | 2021 | <a href="https://eprints.aihta.at/1326">https://eprints.aihta.at/1326</a>   |
| Allogenic bone screw Shark Screw® in patients with hallux valgus or scaphoid fractures/pseudarthroses                                                                                                                     | published | 128                | 2021 | <a href="https://eprints.aihta.at/1327">https://eprints.aihta.at/1327</a>   |
| Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia                                                                                                            | published | 129                | 2021 | <a href="https://eprints.aihta.at/1328">https://eprints.aihta.at/1328</a>   |
| Implantation of Bulking Agents for Faecal Incontinence (1st Update)                                                                                                                                                       | published | 87/1. Update       | 2021 | <a href="https://eprints.aihta.at/1322">https://eprints.aihta.at/1322</a>   |
| Percutaneous coronary interventions (PCI) for chronic total occlusion. Update 2022                                                                                                                                        | published | 64/Update 2022     | 2022 | <a href="https://eprints.aihta.at/1386">https://eprints.aihta.at/1386</a>   |
| Upper airway stimulation for moderate-to-severe sleep apnea. Update 2022                                                                                                                                                  | published | 100/Update 2022    | 2022 | <a href="https://eprints.aihta.at/1387">https://eprints.aihta.at/1387</a>   |
| Subcutaneous implantable cardioverter defibrillator (ICD)                                                                                                                                                                 | published | 109/Update 2022    | 2022 | <a href="https://eprints.aihta.at/1388">https://eprints.aihta.at/1388</a>   |
| Percutaneous Transvascular Implantation of a Coronary Sinus Reducing Stent                                                                                                                                                | published | 121/Update 2022    | 2022 | <a href="https://eprints.aihta.at/1389">https://eprints.aihta.at/1389</a>   |
| Hepatic and portal vein embolization prior to major hepatectomy                                                                                                                                                           | published | 130                | 2022 | <a href="https://eprints.aihta.at/1390">https://eprints.aihta.at/1390</a>   |
| Ultrasound-guided microwave ablation for liver tumors                                                                                                                                                                     | published | 131                | 2022 | <a href="https://eprints.aihta.at/1391">https://eprints.aihta.at/1391</a>   |
| HIS Bundle Pacing for patients requiring permanent pacemaker                                                                                                                                                              | published | 132                | 2022 | <a href="https://eprints.aihta.at/1392">https://eprints.aihta.at/1392</a>   |
| Chemosaturation with percutaneous hepatic perfusions for patients with liver metastases                                                                                                                                   | published | 133                | 2022 | <a href="https://eprints.aihta.at/1393">https://eprints.aihta.at/1393</a>   |
| Lower Esophagel Sphincter Devices for Laparoscopic Surgery in Patients with Gastroesophageal Reflux Disease (GERD): magnetic sphincter augmentation device (MSAD) (Update 101), electric stimulation therapy (update 104) | published | 134                | 2022 | <a href="https://eprints.aihta.at/1394">https://eprints.aihta.at/1394</a>   |
| RefluxStop™ (new)                                                                                                                                                                                                         | published | 103/2. Update 2022 | 2022 | <a href="https://eprints.aihta.at/1407/">https://eprints.aihta.at/1407/</a> |
| Wearable cardioverter-defibrillator (WCD) therapy as prevention of sudden cardiac death in patients at risk – Update 2022                                                                                                 | published | 135                | 2023 | <a href="https://eprints.aihta.at/1454/">https://eprints.aihta.at/1454/</a> |
| Percutaneous aspiration thrombectomy for pulmonary embolism                                                                                                                                                               | published | 136                | 2023 | <a href="https://eprints.aihta.at/1455/">https://eprints.aihta.at/1455/</a> |
| Transcranial magnetic resonance-guided high-intensity focused ultrasound treatment in patients with drug-resistant essential tremor                                                                                       | published | 137                | 2023 | <a href="https://eprints.aihta.at/1456/">https://eprints.aihta.at/1456/</a> |
| Bleomycin Electrosclerotherapy for Vascular Anomalies                                                                                                                                                                     | published | 138                | 2023 | <a href="https://eprints.aihta.at/1457/">https://eprints.aihta.at/1457/</a> |
| Electrical auricular vagus nerve stimulation for pain                                                                                                                                                                     | published | 41/2. Update 2023  | 2023 | <a href="https://eprints.aihta.at/1451/">https://eprints.aihta.at/1451/</a> |
| Percutaneous mitral valve repair with a clip device in patients with mitral regurgitation                                                                                                                                 | published | 111/1. Update 2023 | 2023 | <a href="https://eprints.aihta.at/1452/">https://eprints.aihta.at/1452/</a> |
| Allogeneic mesenchymal stem cells for Crohn's Disease-associated complex perianal fistulas                                                                                                                                | published | 118/1. Update 2023 | 2023 | <a href="https://eprints.aihta.at/1453/">https://eprints.aihta.at/1453/</a> |
| 177Lu-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: Systematic Review                                                                                                        | published | 139                | 2024 | <a href="https://eprints.aihta.at/1525">https://eprints.aihta.at/1525</a>   |
| Caval valve implantation for severe tricuspid regurgitation                                                                                                                                                               | published | 140                | 2024 | <a href="https://eprints.aihta.at/1526">https://eprints.aihta.at/1526</a>   |
| Electroconvulsive therapy in treatment-resistant depression and treatment-resistant schizophrenia                                                                                                                         | published | 141                | 2024 | <a href="https://eprints.aihta.at/1527">https://eprints.aihta.at/1527</a>   |
| Thermoablation for benign thyroid nodules                                                                                                                                                                                 | published | 24/3. Update 2024  | 2024 | <a href="https://eprints.aihta.at/1528">https://eprints.aihta.at/1528</a>   |
| Percutaneous transluminal coronary angioplasty (PTCA) with drug-eluting balloon (DEB) in patients with coronary artery disease (CAD)                                                                                      | published | 45/2. Update 2024  | 2024 | <a href="https://eprints.aihta.at/1529">https://eprints.aihta.at/1529</a>   |
| Renal denervation (RDN) in patients with treatment resistant hypertension                                                                                                                                                 | published | 143                | 2025 | <a href="https://eprints.aihta.at/1564">https://eprints.aihta.at/1564</a>   |
| Islet cell transplantation for pancreatotomy, type 1 diabetes with severe hypoglycemia, and after kidney transplantation                                                                                                  | published | 144                | 2025 | <a href="https://eprints.aihta.at/1565">https://eprints.aihta.at/1565</a>   |
| Drug-coated balloon catheter for treatment of urethral strictures                                                                                                                                                         | published | 145                | 2025 | <a href="https://eprints.aihta.at/1566">https://eprints.aihta.at/1566</a>   |
| Thermoablation as primary or adjunctive therapy for breast cancer                                                                                                                                                         | published |                    |      |                                                                             |

| Title                                                                                                                                                                                    | Status    | No.                | Year | Download/Link                                                               |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------|------|-----------------------------------------------------------------------------|
| One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee                                                                                 | published | 146                | 2025 | <a href="https://eprints.aihta.at/1567">https://eprints.aihta.at/1567</a>   |
| Leadless pacemakers for right ventricle pacing. 3.Update 2025                                                                                                                            | published | 97/3. Update 2024  | 2025 | <a href="https://eprints.aihta.at/1568">https://eprints.aihta.at/1568</a>   |
| Temporary nitinol implantation for the treatment of benign prostatic hyperplasia                                                                                                         | published | 129/1. Update 2024 | 2025 | <a href="https://eprints.aihta.at/1569">https://eprints.aihta.at/1569</a>   |
| Pharyngeal electrical stimulation for neurogenic oropharyngeal dysphagia                                                                                                                 | published | 147                | 2026 | <a href="https://eprints.aihta.at/1614/">https://eprints.aihta.at/1614/</a> |
| Transarterial periarticular embolisation (TAPE) for knee and shoulder osteoarthritis                                                                                                     | published | 148                | 2026 | <a href="https://eprints.aihta.at/1615/">https://eprints.aihta.at/1615/</a> |
| Implantation of a wireless pulmonary artery pressure sensor in patients with advanced heart failure                                                                                      | published | 119/ 1. Update     | 2026 | <a href="https://eprints.aihta.at/1616/">https://eprints.aihta.at/1616/</a> |
| <b>Decision Support Documents: Horizon Scanning in Oncology</b>                                                                                                                          |           |                    |      |                                                                             |
| Azacitidine (Vidaza®) for the treatment of myelodysplastic syndromes                                                                                                                     | published | 1                  | 2009 | <a href="http://eprints.aihta.at/852/">http://eprints.aihta.at/852/</a>     |
| Cetuximab (Erbix®) in EGFR-expressing Non-Small Cell Lung Cancer                                                                                                                         | published | 2                  | 2009 | <a href="http://eprints.aihta.at/856/">http://eprints.aihta.at/856/</a>     |
| Everolimus (Afinitor®) for advanced/metastatic kidney cancer                                                                                                                             | published | 3                  | 2009 | <a href="http://eprints.aihta.at/857/">http://eprints.aihta.at/857/</a>     |
| Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia                                                                                 | published | 4                  | 2009 | <a href="http://eprints.aihta.at/860/">http://eprints.aihta.at/860/</a>     |
| Ibrutinomab tiuxetan (Zevalin®) as consolidation therapy after first remission in patients with follicular lymphoma                                                                      | published | 5                  | 2009 | <a href="http://eprints.aihta.at/861/">http://eprints.aihta.at/861/</a>     |
| Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer                                                                                                           | published | 6                  | 2010 | <a href="http://eprints.aihta.at/868/">http://eprints.aihta.at/868/</a>     |
| Trabectedin (Yondelis®) for second-line recurrent platinum-sensitive ovarian cancer                                                                                                      | published | 7                  | 2010 | <a href="http://eprints.aihta.at/869/">http://eprints.aihta.at/869/</a>     |
| Plerixafor (Mozobil®) for autologous stem cell transplantation in patients with lymphoma and multiple myeloma                                                                            | published | 8                  | 2010 | <a href="http://eprints.aihta.at/878/">http://eprints.aihta.at/878/</a>     |
| Lapatinib ditosylate (Tyverb/Tykerb®) as first-line therapy for the treatment of advanced/metastatic breast cancer                                                                       | published | 9                  | 2010 | <a href="http://eprints.aihta.at/882/">http://eprints.aihta.at/882/</a>     |
| Bendamustine (Ribomustin®/Treanda®/ Levact®) for indolent non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukaemia (CLL) and multiple myeloma                                         | published | 10                 | 2010 | <a href="http://eprints.aihta.at/884/">http://eprints.aihta.at/884/</a>     |
| Panitumumab (Vectibix®) for the first-line treatment of metastatic colorectal cancer                                                                                                     | published | 11                 | 2010 | <a href="http://eprints.aihta.at/880/">http://eprints.aihta.at/880/</a>     |
| Trastuzumab (Herceptin®) in addition to standard chemotherapy as first-line therapy for advanced gastric cancer                                                                          | published | 12                 | 2010 | <a href="http://eprints.aihta.at/881/">http://eprints.aihta.at/881/</a>     |
| Pazopanib (Votrient®) for the treatment of locally advanced and/or metastatic renal cell carcinoma                                                                                       | published | 13                 | 2010 | <a href="http://eprints.aihta.at/902/">http://eprints.aihta.at/902/</a>     |
| Ipilimumab for pre-treated patients with advanced/metastatic melanoma                                                                                                                    | published | 14                 | 2011 | <a href="http://eprints.aihta.at/905/">http://eprints.aihta.at/905/</a>     |
| Nilotinib (Tasigna®) for the 1st-line treatment of Philadelphia chromosome positive chronic myeloid leukemia in the chronic phase                                                        | published | 15                 | 2011 | <a href="http://eprints.aihta.at/906/">http://eprints.aihta.at/906/</a>     |
| Cabazitaxel (Jevtana®) for the second-line therapy of patients with hormone-refractory metastatic prostate cancer                                                                        | published | 16                 | 2011 | <a href="http://eprints.aihta.at/911/">http://eprints.aihta.at/911/</a>     |
| Dasatinib (Sprycel®) for the first-line therapy of patients with newly diagnosed chronic phase philadelphia chromsome positive chronic myeloid leukemia                                  | published | 17                 | 2011 | <a href="http://eprints.aihta.at/910/">http://eprints.aihta.at/910/</a>     |
| Eribulin (Halaven®) as third- or late- line mono-therapy for advanced/metastatic breast cancer                                                                                           | published | 18                 | 2011 | <a href="http://eprints.aihta.at/927/">http://eprints.aihta.at/927/</a>     |
| S-1 (Teysono) in chemotherapy-naïve patients with advanced NSCLC.                                                                                                                        | published | 19                 | 2011 | <a href="http://eprints.aihta.at/931/">http://eprints.aihta.at/931/</a>     |
| Abiraterone acetate (Zytiga™) as 2nd-line therapy for the treatment of metastatic castration-resistant prostate cancer after docetaxel therapy                                           | published | 20                 | 2011 | <a href="http://eprints.aihta.at/938/">http://eprints.aihta.at/938/</a>     |
| Gefitinib (Iressa®) for the 1st-line treatment of non-small cell lung cancer – 1st Update 2011                                                                                           | published | 6/ Update 2011     | 2011 | <a href="http://eprints.aihta.at/935/">http://eprints.aihta.at/935/</a>     |
| Rituximab (Rituxan®/MabThera®) for the first- and second-line treatment of chronic lymphocytic leukaemia - 1st Update 2011                                                               | published | 4/ Update 2011     | 2011 | <a href="http://eprints.aihta.at/937/">http://eprints.aihta.at/937/</a>     |
| Panitumumab (Vectibix®) as 1st line combination therapy for the treatment of WT KRAS metastatic colorectal cancer - 1st Update 2011                                                      | published | 11/ Update 2011    | 2011 | <a href="http://eprints.aihta.at/936/">http://eprints.aihta.at/936/</a>     |
| Axitinib for 2nd-line metastatic renal cell carcinoma                                                                                                                                    | published | 21                 | 2012 | <a href="http://eprints.aihta.at/945/">http://eprints.aihta.at/945/</a>     |
| Erlotinib for the 1st -line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR activating mutations                                                | published | 22                 | 2012 | <a href="http://eprints.aihta.at/941/">http://eprints.aihta.at/941/</a>     |
| Vemurafenib for the 1st –line unresectable stage IIIC or IV melanoma                                                                                                                     | published | 23                 | 2012 | <a href="http://eprints.aihta.at/940/">http://eprints.aihta.at/940/</a>     |
| Everolimus for advanced pancreatic neuroendocrine tumours                                                                                                                                | published | 24                 | 2012 | <a href="http://eprints.aihta.at/942/">http://eprints.aihta.at/942/</a>     |
| Romidepsin for the treatment of peripheral t-cell lymphoma                                                                                                                               | published | 25                 | 2012 | <a href="http://eprints.aihta.at/956/">http://eprints.aihta.at/956/</a>     |
| Brentuximab vedotin for the treatment of Hodgkin Lymphoma and systemic anaplastic large cell lymphoma                                                                                    | published | 26                 | 2012 | <a href="http://eprints.aihta.at/955/">http://eprints.aihta.at/955/</a>     |
| Bevacizumab in combination with chemotherapy regimens for previously treated HER2-negative metastatic breast cancer                                                                      | published | 27                 | 2012 | <a href="http://eprints.aihta.at/952/">http://eprints.aihta.at/952/</a>     |
| Lenalidomide for the treatment of myelodysplastic syndromes                                                                                                                              | published | 28                 | 2012 | <a href="http://eprints.aihta.at/954/">http://eprints.aihta.at/954/</a>     |
| Bortezomib for the treatment of multiple myeloma in a transplant setting                                                                                                                 | published | 29                 | 2012 | <a href="http://eprints.aihta.at/976/">http://eprints.aihta.at/976/</a>     |
| Ipilimumab for the first-line therapy of advanced/metastatic melanoma                                                                                                                    | published | 30                 | 2012 | <a href="http://eprints.aihta.at/970/">http://eprints.aihta.at/970/</a>     |
| Pertuzumab for the first-line therapy of metastatic HER2 positive breast cancer                                                                                                          | published | 31                 | 2012 | <a href="http://eprints.aihta.at/978/">http://eprints.aihta.at/978/</a>     |
| Everolimus for the treatment of breast cancer                                                                                                                                            | published | 32                 | 2012 | <a href="http://eprints.aihta.at/977/">http://eprints.aihta.at/977/</a>     |
| Lenalidomide for the first-line therapy of multiple myeloma                                                                                                                              | published | 33                 | 2012 | <a href="http://eprints.aihta.at/984/">http://eprints.aihta.at/984/</a>     |
| Trametinib for advanced or metastatic BRAF V600E mutation-positive melanoma                                                                                                              | published | 34                 | 2012 | <a href="http://eprints.aihta.at/988/">http://eprints.aihta.at/988/</a>     |
| Crizotinib, PF-01231066 (Xalkori®) for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC).                                           | published | 35                 | 2012 | <a href="http://eprints.aihta.at/993/">http://eprints.aihta.at/993/</a>     |
| Trastuzumab emtansine (Kadcyla™) for previously treated patients with HER2-positive advanced/metastatic breast cancer                                                                    | published | 36                 | 2013 | <a href="http://eprints.aihta.at/998/">http://eprints.aihta.at/998/</a>     |
| Enzalutamide (Xtandi®) for patients with progressive castration-resistant prostate cancer previously treated with docetaxel-based chemotherapy                                           | published | 37                 | 2013 | <a href="http://eprints.aihta.at/997/">http://eprints.aihta.at/997/</a>     |
| Aflibercept (Zaltrap®) in addition to FOLFIRI for the treatment of metastatic colorectal cancer                                                                                          | published | 38                 | 2013 | <a href="http://eprints.aihta.at/999/">http://eprints.aihta.at/999/</a>     |
| Pomalidomide (Pomalyst®) in combination with low-dose dexamethasone vs. high-dose dexamethasone in subjects with refractory multiple myeloma or relapsed and refractory multiple myeloma | published | 39                 | 2013 | <a href="http://eprints.aihta.at/1010/">http://eprints.aihta.at/1010/</a>   |
| Regorafenib (Stivarga®) in pts with metastatic colorectal cancer (CRC) who have progressed after standard therapy                                                                        | published | 40                 | 2013 | <a href="http://eprints.aihta.at/1011/">http://eprints.aihta.at/1011/</a>   |

| Title                                                                                                                                                                                                                             | Status    | No. | Year | Download/Link                                                             |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----|------|---------------------------------------------------------------------------|
| Afatinib (Gilotrif®) for first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s)                                                                 | published | 41  | 2013 | <a href="http://eprints.aihta.at/1020/">http://eprints.aihta.at/1020/</a> |
| Dabrafenib (Tafinlar®) in previously untreated subjects with BRAF mutation-positive advanced (stage III) or metastatic (stage IV) melanoma                                                                                        | published | 42  | 2013 | <a href="http://eprints.aihta.at/1015/">http://eprints.aihta.at/1015/</a> |
| Nab-Paclitaxel (Abraxane®, Ebetaxel®) as first-line therapy for metastatic adenocarcinoma of the pancreas                                                                                                                         | published | 43  | 2014 | <a href="http://eprints.aihta.at/1023/">http://eprints.aihta.at/1023/</a> |
| Radium-223 Dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease                                                     | published | 44  | 2014 | <a href="http://eprints.aihta.at/1024/">http://eprints.aihta.at/1024/</a> |
| Obinutuzumab afutuzumab (Gazyva®) as first line therapy for chronic lymphocytic leukaemia (CLL)                                                                                                                                   | published | 45  | 2014 | <a href="http://eprints.aihta.at/1027/">http://eprints.aihta.at/1027/</a> |
| Bevacizumab (Avastin®) as maintenance therapy for patients with advanced colorectal carcinoma                                                                                                                                     | published | 46  | 2014 | <a href="http://eprints.aihta.at/1034/">http://eprints.aihta.at/1034/</a> |
| Ibrutinib, PCI-32765 (Imbruvica®) for relapsed or refractory CLL                                                                                                                                                                  | published | 47  | 2014 | <a href="http://eprints.aihta.at/1037/">http://eprints.aihta.at/1037/</a> |
| Bevacizumab (Avastin®) for platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer                                                                                                                    | published | 48  | 2014 | <a href="http://eprints.aihta.at/1038/">http://eprints.aihta.at/1038/</a> |
| Idelalisib (Zydelig®) in addition to rituximab for the treatment of relapsed chronic lymphocytic leukaemia                                                                                                                        | published | 49  | 2014 | <a href="http://eprints.aihta.at/1044/">http://eprints.aihta.at/1044/</a> |
| Nivolumab (Opdivo®) as single-agent first-line therapy for unresectable or metastatic melanoma                                                                                                                                    | published | 50  | 2015 | <a href="http://eprints.aihta.at/1051/">http://eprints.aihta.at/1051/</a> |
| Bevacizumab (Avastin®) in combination with chemotherapy as second-line therapy for HER2-negative, locally recurrent or metastatic breast cancer that has progressed after first-line treatment with bevacizumab plus chemotherapy | published | 51  | 2015 | <a href="http://eprints.aihta.at/1066/">http://eprints.aihta.at/1066/</a> |
| Carfilzomib (Kypriolis®) in patients with relapsed multiple myeloma who have received one to three prior lines of therapy                                                                                                         | published | 52  | 2015 | <a href="http://eprints.aihta.at/1070/">http://eprints.aihta.at/1070/</a> |
| Nivolumab (Nivolumab BMS®) for the second-line therapy of metastatic squamous non-small cell lung cancer                                                                                                                          | published | 53  | 2015 | <a href="http://eprints.aihta.at/1068/">http://eprints.aihta.at/1068/</a> |
| Ramucirumab in combination with paclitaxel as second-line treatment for adult patients with advanced gastric or gastro-oesophageal junction carcinoma                                                                             | published | 54  | 2015 | <a href="http://eprints.aihta.at/1069/">http://eprints.aihta.at/1069/</a> |
| Pembrolizumab (Keytruda®) for the treatment of advanced melanoma                                                                                                                                                                  | published | 55  | 2015 | <a href="http://eprints.aihta.at/1076/">http://eprints.aihta.at/1076/</a> |
| Bevacizumab (Avastin®) in addition to standard chemotherapy for the first-line treatment of ovarian cancer                                                                                                                        | published | 56  | 2016 | <a href="http://eprints.aihta.at/1082/">http://eprints.aihta.at/1082/</a> |
| Ofatumumab (Arzerra®) as maintenance therapy in patients with relapsed chronic lymphocytic leukaemia (CLL)                                                                                                                        | published | 57  | 2016 | <a href="http://eprints.aihta.at/1085/">http://eprints.aihta.at/1085/</a> |
| Pembrolizumab (Keytruda®) in previously treated advanced non-small cell lung cancer (NSCLC)                                                                                                                                       | published | 58  | 2016 | <a href="http://eprints.aihta.at/1086/">http://eprints.aihta.at/1086/</a> |
| Afatinib (Gilotrif®) in patients with non-small cell lung cancer (NSCLC) who are refractory to erlotinib/gefitinib and afatinib monotherapy                                                                                       | published | 59  | 2016 | <a href="http://eprints.aihta.at/1089/">http://eprints.aihta.at/1089/</a> |
| Obinutuzumab (Gazyvaro®) in combination with bendamustine for the treatment of relapsed/refractory follicular lymphoma (FL)                                                                                                       | published | 60  | 2016 | <a href="http://eprints.aihta.at/1100/">http://eprints.aihta.at/1100/</a> |
| Atezolizumab (Tecentriq™) for the treatment of locally advanced and metastatic urothelial carcinoma                                                                                                                               | published | 61  | 2016 | <a href="http://eprints.aihta.at/1104/">http://eprints.aihta.at/1104/</a> |
| Venetoclax (Venclexta™) for the treatment of relapsed or refractory chronic lymphocytic leukaemia (CLL) with chromosome 17p deletion                                                                                              | published | 62  | 2016 | <a href="http://eprints.aihta.at/1105/">http://eprints.aihta.at/1105/</a> |
| Ixazomib (Ninlaro®) in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma (MM)                                                                                                                 | published | 63  | 2016 | <a href="http://eprints.aihta.at/1111/">http://eprints.aihta.at/1111/</a> |
| Palbociclib (Ibrance®) in combination with fulvestrant for the treatment of hormone-receptor-positive, HER2-negative advanced or metastatic breast cancer                                                                         | published | 64  | 2017 | <a href="http://eprints.aihta.at/1114/">http://eprints.aihta.at/1114/</a> |
| Ribociclib in combination with letrozole for the first-line therapy of HR-positive, HER2-negative recurrent or metastatic breast cancer                                                                                           | published | 65  | 2017 | <a href="http://eprints.aihta.at/1115/">http://eprints.aihta.at/1115/</a> |
| Neratinib for the treatment of patients with HER2-positive breast cancer after trastuzumab-based adjuvant therapy                                                                                                                 | published | 66  | 2017 | <a href="http://eprints.aihta.at/1116/">http://eprints.aihta.at/1116/</a> |
| Ipilimumab (Yervoy®) in the adjuvant therapy for high-risk stage III cutaneous melanoma                                                                                                                                           | published | 67  | 2017 | <a href="http://eprints.aihta.at/1119/">http://eprints.aihta.at/1119/</a> |
| Atezolizumab (Tecentriq®) in previously treated non-small cell lung cancer (NSCLC)                                                                                                                                                | published | 68  | 2017 | <a href="http://eprints.aihta.at/1120/">http://eprints.aihta.at/1120/</a> |
| Ceritinib (Zykadia®) as first-line therapy for patients with advanced ALK-positive non-small cell lung cancer                                                                                                                     | published | 69  | 2017 | <a href="http://eprints.aihta.at/1123/">http://eprints.aihta.at/1123/</a> |
| Pembrolizumab (Keytruda®) as second-line treatment for patients with advanced urothelial carcinoma (UC)                                                                                                                           | published | 70  | 2017 | <a href="http://eprints.aihta.at/1124/">http://eprints.aihta.at/1124/</a> |
| Olaparib (Lynparza®) in patients with BRCA-mutated metastatic breast cancer                                                                                                                                                       | published | 71  | 2017 | <a href="http://eprints.aihta.at/1136/">http://eprints.aihta.at/1136/</a> |
| Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC)                                                                                                  | published | 72  | 2017 | <a href="http://eprints.aihta.at/1137/">http://eprints.aihta.at/1137/</a> |
| Regorafenib indicated as monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib. EUnetHTA report                                                           | published | 73  | 2017 | <a href="http://eprints.aihta.at/1138/">http://eprints.aihta.at/1138/</a> |
| Midostaurin with standard chemotherapy in FLT3-Positive Acute Myeloid Leukaemia                                                                                                                                                   | published | 74  | 2017 | <a href="http://eprints.aihta.at/1140/">http://eprints.aihta.at/1140/</a> |
| Nivolumab (Opdivo®) for metastatic DNA mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)                                                                                        | published | 75  | 2017 | <a href="http://eprints.aihta.at/1144/">http://eprints.aihta.at/1144/</a> |
| Durvalumab (Imfinzi™) for the treatment of patients with stage III non-small-cell lung cancer after prior chemoradiotherapy                                                                                                       | published | 76  | 2017 | <a href="http://eprints.aihta.at/1145/">http://eprints.aihta.at/1145/</a> |
| Alectinib as monotherapy for the first-line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)                                                                                             | published | 77  | 2018 | <a href="http://eprints.aihta.at/1152/">http://eprints.aihta.at/1152/</a> |
| Abemaciclib (Verzenio®) in combination with a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for advanced breast cancer (ABC)                                                                                         | published | 78  | 2018 | <a href="http://eprints.aihta.at/1154/">http://eprints.aihta.at/1154/</a> |
| Rituximab (MabThera®) after autologous stem-cell transplantation (ASCT) in mantle cell lymphoma (MCL)                                                                                                                             | published | 79  | 2018 | <a href="http://eprints.aihta.at/1155/">http://eprints.aihta.at/1155/</a> |
| Osimertinib (Tagrisso®) for the initial treatment of EGFR-mutated advanced non-small-cell lung cancer (NSCLC)                                                                                                                     | published | 80  | 2018 | <a href="http://eprints.aihta.at/1160/">http://eprints.aihta.at/1160/</a> |
| Daratumumab (Darzalex®) in combination with bortezomib, melphalan and prednisone for untreated myeloma                                                                                                                            | published | 81  | 2018 | <a href="http://eprints.aihta.at/1161/">http://eprints.aihta.at/1161/</a> |
| Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the first-line treatment of patients with advanced RCC                                                                                                           | published | 82  | 2018 | <a href="http://eprints.aihta.at/1175/">http://eprints.aihta.at/1175/</a> |
| Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of metastatic non-small-cell lung cancer (NSCLC)                                                                                                     | published | 83  | 2018 | <a href="http://eprints.aihta.at/1176/">http://eprints.aihta.at/1176/</a> |
| Enzalutamide (Xtandi®) in patients with nonmetastatic, castration-resistant prostate cancer (CRPC)                                                                                                                                | published | 84  | 2018 | <a href="http://eprints.aihta.at/1184/">http://eprints.aihta.at/1184/</a> |
| Ibrutinib (Imbruvica®) in combination with rituximab for the treatment of Waldenström's macroglobulinemia                                                                                                                         | published | 85  | 2018 | <a href="http://eprints.aihta.at/1185/">http://eprints.aihta.at/1185/</a> |
| Olaparib (Lynparza®) für die Erstlinien-Erhaltungstherapie von Patientinnen mit neu diagnostiziertem, fortgeschrittenem Ovarialkarzinom                                                                                           | published | 86  | 2019 | <a href="http://eprints.aihta.at/1192/">http://eprints.aihta.at/1192/</a> |
| Atezolizumab (Tecentriq®) und Nab-Paclitaxel (Abraxane®) für die Behandlung von Patientinnen mit fortgeschrittenem, triple-negativem Mammakarzinom (aTNBC)                                                                        | published | 87  | 2019 | <a href="http://eprints.aihta.at/1193/">http://eprints.aihta.at/1193/</a> |
| Darolutamide für die Behandlung von Patienten mit nichtmetastatischem, kastrationsresistentem Prostatakarzinom                                                                                                                    | published | 88  | 2019 | <a href="http://eprints.aihta.at/1199/">http://eprints.aihta.at/1199/</a> |
| Brentuximab vedotin (Adcetris®) in combination with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCLs)                                                                                                             | published | 89  | 2019 | <a href="http://eprints.aihta.at/1210/">http://eprints.aihta.at/1210/</a> |
| Enzalutamide (Xtandi®) in addition to standard first-line therapy in men with metastatic hormone-sensitive prostate cancer (mHSPC)                                                                                                | published | 90  | 2019 | <a href="http://eprints.aihta.at/1216/">http://eprints.aihta.at/1216/</a> |
| Pembrolizumab (Keytruda®) as first-line therapy for PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (NSCLC)                                                                                           | published | 91  | 2019 | <a href="http://eprints.aihta.at/1219/">http://eprints.aihta.at/1219/</a> |

| Title                                                                                                                                                                    | Status    | No. | Year | Download/Link                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----|------|-----------------------------------------------------------------------------|
| <b>HTA-Informationsdienst Rapid Reviews</b>                                                                                                                              |           |     |      |                                                                             |
| iv Immunoglobulins (IgVena) in recurrent in vitro fertilisation implantation failure and/or recurrent pregnancy loss                                                     | published | 1   | 2024 | <a href="https://eprints.aihta.at/1434/">https://eprints.aihta.at/1434/</a> |
| Extracorporeal shock wave therapy for orthopaedic indications                                                                                                            | published | 2   | 2024 | <a href="https://eprints.aihta.at/1435/">https://eprints.aihta.at/1435/</a> |
| Radiofrequency denervation for chronic lumbar or cervical spine pain                                                                                                     | published | 3   | 2024 | <a href="https://eprints.aihta.at/1448/">https://eprints.aihta.at/1448/</a> |
| Biomarkers in Alzheimer's Disease                                                                                                                                        | published | 4   | 2024 | <a href="https://eprints.aihta.at/1471/">https://eprints.aihta.at/1471/</a> |
| Robot-assisted rehabilitation for incomplete spinal cord injury                                                                                                          | published | 5   | 2024 | <a href="https://eprints.aihta.at/1478/">https://eprints.aihta.at/1478/</a> |
| Myopia control spectacle lenses for children and adolescents                                                                                                             | published | 6   | 2024 | <a href="https://eprints.aihta.at/1488/">https://eprints.aihta.at/1488/</a> |
| Autologous fat grafting in osteoarthritis                                                                                                                                | published | 7   | 2024 | <a href="https://eprints.aihta.at/1490/">https://eprints.aihta.at/1490/</a> |
| Endovenous laser therapy for varicose veins in the lower extremities                                                                                                     | published | 8   | 2024 | <a href="https://eprints.aihta.at/1490/">https://eprints.aihta.at/1490/</a> |
| Liposuction for the removal of subcutaneous (large) lipomas                                                                                                              | published | 9   | 2024 | <a href="https://eprints.aihta.at/1498/">https://eprints.aihta.at/1498/</a> |
| Biomarkers in Parkinson's Disease                                                                                                                                        | published | 10  | 2024 | <a href="https://eprints.aihta.at/1500/">https://eprints.aihta.at/1500/</a> |
| Calcitonin gene-related peptide antagonists for the prevention of migraine - summary of the BAG /RACS HTA report 2023                                                    | published | 11  | 2024 | <a href="https://eprints.aihta.at/1504/">https://eprints.aihta.at/1504/</a> |
| Use of telepathology for intraoperative frozen section examination                                                                                                       | published | 12  | 2024 | <a href="https://eprints.aihta.at/1505/">https://eprints.aihta.at/1505/</a> |
| CAR-based immunotherapy with a focus on CAR-NK cells                                                                                                                     | published | 13  | 2024 | <a href="https://eprints.aihta.at/1513/">https://eprints.aihta.at/1513/</a> |
| Skin cancer prevention: Guideline recommendations for primary and secondary prevention                                                                                   | published | 14  | 2024 | <a href="https://eprints.aihta.at/1514/">https://eprints.aihta.at/1514/</a> |
| Massive parallel sequencing – technologies for high-throughput analysis of genetic-genomic data sets                                                                     | published | 15  | 2024 | <a href="https://eprints.aihta.at/1536/">https://eprints.aihta.at/1536/</a> |
| Reimbursement models and pricing of digital health technologies and telemonitoring applications                                                                          | published | 16  | 2025 | <a href="https://eprints.aihta.at/1556/">https://eprints.aihta.at/1556/</a> |
| Serum eye drops for patients with severe ocular surface diseases                                                                                                         | published | 17  | 2025 | <a href="https://eprints.aihta.at/1559/">https://eprints.aihta.at/1559/</a> |
| Telerehabilitation for Movement Support in People with Chronic Back Pain – Rapid Review of Effectiveness                                                                 | published | 18  | 2025 | <a href="https://eprints.aihta.at/1561/">https://eprints.aihta.at/1561/</a> |
| Enfortumab Vedotin in combination with Pembrolizumab in Urothelial Cancer                                                                                                | published | 19  | 2025 | <a href="https://eprints.aihta.at/1575/">https://eprints.aihta.at/1575/</a> |
| Infiltration therapies for musculoskeletal pain: intradermal whealing                                                                                                    | published | 20  | 2026 | <a href="https://eprints.aihta.at/1610/">https://eprints.aihta.at/1610/</a> |
| <b>Decision Support Documents: Oncology Fact Scheets</b>                                                                                                                 |           |     |      |                                                                             |
| Venetoclax (Venclyxto®) and obinutuzumab in patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions                                                  | published | 1   | 2020 | <a href="http://eprints.aihta.at/1229/">http://eprints.aihta.at/1229/</a>   |
| Darolutamide (Nubeqa®) in nonmetastatic, castration-resistant prostate cancer (nmCRPC)                                                                                   | published | 2   | 2020 | <a href="http://eprints.aihta.at/1230/">http://eprints.aihta.at/1230/</a>   |
| Rituximab (MabThera®) for the treatment of paediatric patients with previously untreated advanced stage CD20 positive DLBCL, BL, BAL, or BLL                             | published | 3   | 2020 | <a href="http://eprints.aihta.at/1231/">http://eprints.aihta.at/1231/</a>   |
| Brigatinib (Alunbrig®) in ALK-positive non–small-cell lung cancer (NSCLC)                                                                                                | published | 4   | 2020 | <a href="http://eprints.aihta.at/1232/">http://eprints.aihta.at/1232/</a>   |
| Brentuximab vedotin (Adcetris®) with chemotherapy for CD30-positive peripheral T-cell lymphoma (PTCL)                                                                    | published | 5   | 2020 | <a href="http://eprints.aihta.at/1235/">http://eprints.aihta.at/1235/</a>   |
| Isatuximab (Sarclisa®) plus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (MM)                                       | published | 6   | 2020 | <a href="http://eprints.aihta.at/1236/">http://eprints.aihta.at/1236/</a>   |
| Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation            | published | 7   | 2020 | <a href="http://eprints.aihta.at/1240/">http://eprints.aihta.at/1240/</a>   |
| Cabazitaxel Accord for the treatment of patients with metastatic castration resistant prostate cancer (mCRPC) previously treated with a docetaxel containing regimen     | published | 8   | 2020 | <a href="http://eprints.aihta.at/1241/">http://eprints.aihta.at/1241/</a>   |
| Daratumumab (Darzalex®) in a new pharmaceutical form associated with a new strength and a new route of administration for the treatment of multiple myeloma              | published | 9   | 2020 | <a href="http://eprints.aihta.at/1242/">http://eprints.aihta.at/1242/</a>   |
| Glasdegib (Daurismo®) with low-dose cytarabine (LDAC) in patients with newly diagnosed acute myeloid leukaemia (AML)                                                     | published | 10  | 2020 | <a href="http://eprints.aihta.at/1243/">http://eprints.aihta.at/1243/</a>   |
| Maintenance olaparib (Lynparza®) for the treatment of patients with germline BRCA-mutated metastatic pancreatic cancer                                                   | published | 11  | 2020 | <a href="http://eprints.aihta.at/1246/">http://eprints.aihta.at/1246/</a>   |
| Alpelisib (Piqray®) plus fulvestrant for PIK3CA-mutated, hormone receptor–positive advanced breast cancer                                                                | published | 12  | 2020 | <a href="http://eprints.aihta.at/1247/">http://eprints.aihta.at/1247/</a>   |
| Entrectinib (Rozlytrek®) for the treatment of patients whose solid tumours have a NTRK gene fusion, or patients with ROS1-positive advanced NSCLC                        | published | 13  | 2020 | <a href="http://eprints.aihta.at/1248/">http://eprints.aihta.at/1248/</a>   |
| Carmustine (Carmustine Obvius®) as conditioning treatment before transplantation in patients with Hodgkin's lymphoma (HL) and non-Hodgkin's lymphomas (NHL)              | published | 14  | 2020 | <a href="https://eprints.aihta.at/1261/">https://eprints.aihta.at/1261/</a> |
| Acalabrutinib (Calquence®) for the treatment of chronic lymphocytic leukaemia (CLL)                                                                                      | published | 15  | 2020 | <a href="https://eprints.aihta.at/1263/">https://eprints.aihta.at/1263/</a> |
| Avapritinib (Ayyavkyt®) for the treatment of gastrointestinal stromal tumours (GIST)                                                                                     | published | 16  | 2020 | <a href="https://eprints.aihta.at/1264/">https://eprints.aihta.at/1264/</a> |
| Belantamab mafodotin (Blenrep®) as monotherapy for the treatment of relapsed or refractory multiple myeloma (MM)                                                         | published | 17  | 2020 | <a href="https://eprints.aihta.at/1265/">https://eprints.aihta.at/1265/</a> |
| Durvalumab (Imfinzi®) in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC) | published | 18  | 2020 | <a href="https://eprints.aihta.at/1266/">https://eprints.aihta.at/1266/</a> |
| Ibrutinib (Imbruvica®) as a single agent or in combination with rituximab or obinutuzumab for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)  | published | 19  | 2020 | <a href="https://eprints.aihta.at/1267/">https://eprints.aihta.at/1267/</a> |
| Atezolizumab (Tecentriq®) plus bevacizumab for the treatment of advanced or unresectable hepatocellular carcinoma (HCC)                                                  | published | 20  | 2020 | <a href="https://eprints.aihta.at/1270/">https://eprints.aihta.at/1270/</a> |
| Nivolumab (Opdivo®) plus ipilimumab (Yervoy®) and chemotherapy as first-line treatment for metastatic non-small cell lung cancer (NSCLC)                                 | published | 21  | 2020 | <a href="https://eprints.aihta.at/1271/">https://eprints.aihta.at/1271/</a> |
| Niraparib (Zejula®) in patients with newly diagnosed advanced ovarian cancer                                                                                             | published | 22  | 2020 | <a href="https://eprints.aihta.at/1272/">https://eprints.aihta.at/1272/</a> |
| Olaparib (Lynparza®) for metastatic castration-resistant prostate cancer (mCRPC)                                                                                         | published | 23  | 2020 | <a href="https://eprints.aihta.at/1273/">https://eprints.aihta.at/1273/</a> |
| Olaparib (Lynparza®) plus bevacizumab as first-line maintenance treatment in patients with ovarian cancer                                                                | published | 24  | 2020 | <a href="https://eprints.aihta.at/1274/">https://eprints.aihta.at/1274/</a> |
| Blinatumomab (Blinicyto®) for the treatment of patients with Philadelphia chromosome positive B-precursor acute lymphoblastic leukaemia (ALL)                            | published | 25  | 2020 | <a href="https://eprints.aihta.at/1276/">https://eprints.aihta.at/1276/</a> |
| Nivolumab (Opdivo®) as monotherapy for the treatment of unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma (OESCC)                       | published | 26  | 2020 | <a href="https://eprints.aihta.at/1277/">https://eprints.aihta.at/1277/</a> |
| Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of relapsed or refractory mantle cell lymphoma (MCL)                                            | published | 27  | 2020 | <a href="https://eprints.aihta.at/1278/">https://eprints.aihta.at/1278/</a> |
| Tagraxofusp (Elzonris®) in blastic plasmacytoid dendritic-cell neoplasm (BPDCN)                                                                                          | published | 28  | 2020 | <a href="https://eprints.aihta.at/1284/">https://eprints.aihta.at/1284/</a> |
| Carfilzomib (Kyprolis®) with daratumumab and dexamethasone for the treatment of adult patients with multiple myeloma (MM)                                                | published | 29  | 2020 | <a href="https://eprints.aihta.at/1285/">https://eprints.aihta.at/1285/</a> |

| Title                                                                                                                                                                                                                                            | Status     | No. | Year | Download/Link                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------------------------------------------------|
| A fixed-dose combination of pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo™) for the treatment of early and metastatic breast cancer                                                                                                     | published  | 30  | 2020 | <a href="https://eprints.aihta.at/1286/">https://eprints.aihta.at/1286/</a> |
| Avelumab (Bavencio®) as monotherapy for the first-line maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma                                                                                                | published  | 31  | 2020 | <a href="https://eprints.aihta.at/1287/">https://eprints.aihta.at/1287/</a> |
| Trastuzumab deruxtecan (Enhertu®) in patients with previously treated HER2-positive breast cancer                                                                                                                                                | published  | 32  | 2021 | <a href="https://eprints.aihta.at/1288/">https://eprints.aihta.at/1288/</a> |
| Fedratinib (Inrebic®) for the treatment of primary and secondary myelofibrosis                                                                                                                                                                   | published  | 33  | 2020 | <a href="https://eprints.aihta.at/1289/">https://eprints.aihta.at/1289/</a> |
| Pembrolizumab (Keytruda®) as monotherapy for the first-line treatment of MSI H or dMMR colorectal cancer                                                                                                                                         | published  | 34  | 2021 | <a href="https://eprints.aihta.at/1290/">https://eprints.aihta.at/1290/</a> |
| Moxetumomab pasudotox (Lumoxiti®) for the treatment of patients with relapsed or refractory hairy cell leukaemia (HCL)                                                                                                                           | published  | 35  | 2021 | <a href="https://eprints.aihta.at/1291/">https://eprints.aihta.at/1291/</a> |
| Selpercatinib (Retsevmo®) for the treatment of RET-fusion positive NSCLC, RET-fusion positive thyroid cancer and RET-mutant medullary-thyroid cancer                                                                                             | published  | 36  | 2021 | <a href="https://eprints.aihta.at/1292/">https://eprints.aihta.at/1292/</a> |
| Tucatinib (Tukysa®) with trastuzumab and capecitabine for the treatment of HER2-positive locally advanced or metastatic breast cancer                                                                                                            | published  | 37  | 2021 | <a href="https://eprints.aihta.at/1293/">https://eprints.aihta.at/1293/</a> |
| Pembrolizumab (Keytruda®) is indicated for the treatment of adult and paediatric patients with relapsed or refractory classical Hodgkin lymphoma (cHL)                                                                                           | published  | 38  | 2021 | <a href="https://eprints.aihta.at/1296/">https://eprints.aihta.at/1296/</a> |
| Selinexor (Nexpovio®) in combination with dexamethasone for the treatment of relapsed and refractory multiple myeloma (MM)                                                                                                                       | published  | 39  | 2021 | <a href="https://eprints.aihta.at/1297/">https://eprints.aihta.at/1297/</a> |
| Pemigatinib (Pemazyre®) for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement                                                            | published  | 40  | 2021 | <a href="https://eprints.aihta.at/1298/">https://eprints.aihta.at/1298/</a> |
| Dostarlimab (Jemperli®) for the treatment of patients with recurrent or advanced mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer (EC)                                                                | published  | 41  | 2021 | <a href="https://eprints.aihta.at/1299/">https://eprints.aihta.at/1299/</a> |
| Nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) for the first-line treatment of patients with advanced renal cell carcinoma (RCC)                                                                                              | published  | 42  | 2021 | <a href="https://eprints.aihta.at/1300/">https://eprints.aihta.at/1300/</a> |
| Isatuximab (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of patients with multiple myeloma (MM)                                                                                                                | published  | 43  | 2021 | <a href="https://eprints.aihta.at/1301/">https://eprints.aihta.at/1301/</a> |
| Duvelisib (Copiktra®) for the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) and refractory follicular lymphoma (FL)                                                                                      | published  | 44  | 2021 | <a href="https://eprints.aihta.at/1304/">https://eprints.aihta.at/1304/</a> |
| Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC)                                                                                                       | published  | 45  | 2021 | <a href="https://eprints.aihta.at/1305/">https://eprints.aihta.at/1305/</a> |
| Enzalutamide (Xtandi®) for the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)                                                                           | published  | 46  | 2021 | <a href="https://eprints.aihta.at/1306/">https://eprints.aihta.at/1306/</a> |
| Azacitidine (Onureg®) for the maintenance treatment of patients with acute myeloid leukaemia (AML)                                                                                                                                               | published  | 47  | 2021 | <a href="https://eprints.aihta.at/1309/">https://eprints.aihta.at/1309/</a> |
| Osimertinib (Tagrisso®) as monotherapy for the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC)                                                                        | published  | 48  | 2021 | <a href="https://eprints.aihta.at/1310/">https://eprints.aihta.at/1310/</a> |
| Venetoclax (Venclyxto®) in combination with a hypomethylating agent for the treatment of patients with newly diagnosed acute myeloid leukaemia (AML)                                                                                             | published  | 49  | 2021 | <a href="https://eprints.aihta.at/1311/">https://eprints.aihta.at/1311/</a> |
| Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)                                                                                                                      | published  | 52  | 2021 | <a href="https://eprints.aihta.at/1316/">https://eprints.aihta.at/1316/</a> |
| Nivolumab (Opdivo®) in combination with ipilimumab (Yervoy®) for the treatment of patients with mismatch repair deficient (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer                                         | publiziert | 51  | 2020 | <a href="https://eprints.aihta.at/1315/">https://eprints.aihta.at/1315/</a> |
| Cemiplimab (Libtayo®) as monotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC)                                                                                                                      | publiziert | 52  | 2020 | <a href="https://eprints.aihta.at/1316/">https://eprints.aihta.at/1316/</a> |
| Cemiplimab (Libtayo®) as monotherapy for the treatment of locally advanced or metastatic basal cell carcinoma (laBCC or mBCC)                                                                                                                    | published  | 53  | 2021 | <a href="https://eprints.aihta.at/1317/">https://eprints.aihta.at/1317/</a> |
| Pembrolizumab (Keytruda®) in combination with platinum and fluoropyrimidine based chemotherapy for the treatment of locally advanced unresectable or metastatic carcinoma of the oesophagus                                                      | published  | 54  | 2021 | <a href="https://eprints.aihta.at/1318/">https://eprints.aihta.at/1318/</a> |
| Daratumumab (Darzalex®) in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma (MM)                                                                                                                            | published  | 55  | 2021 | <a href="https://eprints.aihta.at/1319/">https://eprints.aihta.at/1319/</a> |
| Daratumumab (Darzalex®) in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of newly diagnosed systemic light chain (AL) amyloidosis                                                                            | published  | 56  | 2021 | <a href="https://eprints.aihta.at/1320/">https://eprints.aihta.at/1320/</a> |
| Idecabtagene vicleuceel (Abecma®) for the treatment of patients with relapsed and refractory multiple myeloma (MM)                                                                                                                               | published  | 57  | 2021 | <a href="https://eprints.aihta.at/1330/">https://eprints.aihta.at/1330/</a> |
| Tafasitamab (Minjivi®, Monjuvi®) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)                                                                                                                 | published  | 58  | 2021 | <a href="https://eprints.aihta.at/1331/">https://eprints.aihta.at/1331/</a> |
| Adjuvant nivolumab (Opdivo®) as monotherapy for the treatment of patients with oesophageal (OC) or gastro-oesophageal junction cancer (GEJC)                                                                                                     | published  | 59  | 2021 | <a href="https://eprints.aihta.at/1332/">https://eprints.aihta.at/1332/</a> |
| Zanubrutinib (Brukinsa®) as monotherapy for the treatment of patients with waldenström's macroglobulinaemia (WM)                                                                                                                                 | published  | 60  | 2021 | <a href="https://eprints.aihta.at/1336/">https://eprints.aihta.at/1336/</a> |
| Pralsetinib (Gavreto®) as monotherapy for the treatment of patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC)                                                                        | published  | 61  | 2021 | <a href="https://eprints.aihta.at/1337/">https://eprints.aihta.at/1337/</a> |
| Ripretinib (Qinlock®) for the treatment of patients with advanced gastrointestinal stromal tumour (GIST)                                                                                                                                         | published  | 62  | 2021 | <a href="https://eprints.aihta.at/1338/">https://eprints.aihta.at/1338/</a> |
| Nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-based combination chemotherapy for the treatment of patients with HER2?negative advanced or metastatic gastric, gastro?oesophageal junction or oesophageal adenocarcinoma | published  | 63  | 2021 | <a href="https://eprints.aihta.at/1339/">https://eprints.aihta.at/1339/</a> |
| Pembrolizumab (Keytruda®) in combination with chemotherapy for the treatment of locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC)                                                                                | published  | 64  | 2021 | <a href="https://eprints.aihta.at/1340/">https://eprints.aihta.at/1340/</a> |
| Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)                                                                                                             | published  | 67  | 2021 | <a href="https://eprints.aihta.at/1343/">https://eprints.aihta.at/1343/</a> |
| Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the treatment of advanced or recurrent endometrial carcinoma (EC)                                                                                                          | published  | 68  | 2021 | <a href="https://eprints.aihta.at/1344/">https://eprints.aihta.at/1344/</a> |
| Amivantamab (Rybrevant) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)                                                                                                                            | published  | 69  | 2021 | <a href="https://eprints.aihta.at/1345/">https://eprints.aihta.at/1345/</a> |
| Sacituzumab govitecan (Trodelvy) as monotherapy for the treatment of patients with unresectable or metastatic triple-negative breast cancer (mTNBC)                                                                                              | published  | 70  | 2021 | <a href="https://eprints.aihta.at/1346/">https://eprints.aihta.at/1346/</a> |
| Sotorasib (Lumykras®): Sotorasib (Lumykras®) as monotherapy for the treatment of advanced NSCLC with KRAS G12C mutation                                                                                                                          | published  | 71  | 2021 | <a href="https://eprints.aihta.at/1347/">https://eprints.aihta.at/1347/</a> |
| Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer                                                                                                                  | published  | 72  | 2022 | <a href="https://eprints.aihta.at/1353/">https://eprints.aihta.at/1353/</a> |
| Tepotinib (Tepmetko®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC)                                                                                                                              | published  | 73  | 2022 | <a href="https://eprints.aihta.at/1354/">https://eprints.aihta.at/1354/</a> |
| Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of renal cell carcinoma (RCC)                                                                                                                                                | published  | 74  | 2022 | <a href="https://eprints.aihta.at/1355/">https://eprints.aihta.at/1355/</a> |
| Lorlatinib (Lorviqua®) as monotherapy for the treatment of anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC)                                                                                                 | published  | 75  | 2022 | <a href="https://eprints.aihta.at/1356/">https://eprints.aihta.at/1356/</a> |
| Tegafur/gimeracil/oteracil (Teysono®) for the treatment of metastatic colorectal cancer                                                                                                                                                          | published  | 76  | 2022 | <a href="https://eprints.aihta.at/1357/">https://eprints.aihta.at/1357/</a> |
| Lisocabtagene maraleuceel (Breyanzi) for the treatment of relapsed or refractory DLBCL                                                                                                                                                           | published  | 77  | 2022 | <a href="https://eprints.aihta.at/1359/">https://eprints.aihta.at/1359/</a> |
| Avapritinib (Avykyt®) for the treatment of advanced systemic mastocytosis (AdvSM)                                                                                                                                                                | published  | 78  | 2022 | <a href="https://eprints.aihta.at/1360/">https://eprints.aihta.at/1360/</a> |
| Tebentafusp (Kimmtrak®) bei Uveal melanoma                                                                                                                                                                                                       | published  | 79  | 2022 | <a href="https://eprints.aihta.at/1361/">https://eprints.aihta.at/1361/</a> |
| Relugolix (Orgovyx®) bei Prostate Cancer                                                                                                                                                                                                         | published  | 80  | 2022 | <a href="https://eprints.aihta.at/1362/">https://eprints.aihta.at/1362/</a> |
| Nivolumab (Opdivo®) bei MIUC                                                                                                                                                                                                                     | published  | 81  | 2022 | <a href="https://eprints.aihta.at/1363/">https://eprints.aihta.at/1363/</a> |

| Title                                                                                                                                                                                                                                            | Status    | No. | Year | Download/Link                                                               |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----|------|-----------------------------------------------------------------------------|
| Ipilimumab (Yervoy®) + Nivolumab (Opdivo®) bei OSCC                                                                                                                                                                                              | published | 82  | 2022 | <a href="https://eprints.aihta.at/1364/">https://eprints.aihta.at/1364/</a> |
| Nivolumab (Opdivo®) + chemotherapy bei OSCC                                                                                                                                                                                                      | published | 83  | 2022 | <a href="https://eprints.aihta.at/1365/">https://eprints.aihta.at/1365/</a> |
| Abemaciclib (Verzenio®) bei early breast cancer                                                                                                                                                                                                  | published | 84  | 2022 | <a href="https://eprints.aihta.at/1366/">https://eprints.aihta.at/1366/</a> |
| Enfortumab vedotin (Padcev®) as monotherapy for the treatment of patients with locally advanced or metastatic urothelial cancer                                                                                                                  | published | 85  | 2022 | <a href="https://eprints.aihta.at/1367/">https://eprints.aihta.at/1367/</a> |
| Ciltacabtagene autoleucel (Carvykti®) for the treatment of multiple myeloma (MM)                                                                                                                                                                 | published | 86  | 2022 | <a href="https://eprints.aihta.at/1371/">https://eprints.aihta.at/1371/</a> |
| Cabozantinib (Cabometyx®) as monotherapy for the treatment of thyroid carcinoma (DTC)                                                                                                                                                            | published | 87  | 2022 | <a href="https://eprints.aihta.at/1372/">https://eprints.aihta.at/1372/</a> |
| Tisagenlecleucel (Kymriah®) for the treatment of follicular lymphoma (FL) after two or more lines of systemic therapy                                                                                                                            | published | 88  | 2022 | <a href="https://eprints.aihta.at/1373/">https://eprints.aihta.at/1373/</a> |
| Polatuzumab vedotin (Polivy®) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of B-cell lymphoma (DLBCL)                                                                                  | published | 89  | 2022 | <a href="https://eprints.aihta.at/1374/">https://eprints.aihta.at/1374/</a> |
| Pembrolizumab (Keytruda®) as monotherapy in adults with colorectal cancer                                                                                                                                                                        | published | 90  | 2022 | <a href="https://eprints.aihta.at/1375/">https://eprints.aihta.at/1375/</a> |
| Pembrolizumab (Keytruda®) in combination with chemotherapy with or without bevacizumab for cervical cancer                                                                                                                                       | published | 91  | 2022 | <a href="https://eprints.aihta.at/1376/">https://eprints.aihta.at/1376/</a> |
| Mosunetuzumab (Lunsumio®) Follicular lymphoma                                                                                                                                                                                                    | published | 92  | 2022 | <a href="https://eprints.aihta.at/1377/">https://eprints.aihta.at/1377/</a> |
| Capmatinib (Tabrecta®) NSCLC                                                                                                                                                                                                                     | published | 93  | 2022 | <a href="https://eprints.aihta.at/1378/">https://eprints.aihta.at/1378/</a> |
| Pembrolizumab (Keytruda®) TNBC                                                                                                                                                                                                                   | published | 94  | 2022 | <a href="https://eprints.aihta.at/1379/">https://eprints.aihta.at/1379/</a> |
| Selpercatinib (Retsevmo®) NSCLC                                                                                                                                                                                                                  | published | 95  | 2022 | <a href="https://eprints.aihta.at/1380/">https://eprints.aihta.at/1380/</a> |
| Atezolizumab (Tecentriq®) NSCLC                                                                                                                                                                                                                  | published | 96  | 2022 | <a href="https://eprints.aihta.at/1381/">https://eprints.aihta.at/1381/</a> |
| Axicabtagene ciloleucel (Yescarta®) Follicular lymphoma                                                                                                                                                                                          | published | 97  | 2022 | <a href="https://eprints.aihta.at/1382/">https://eprints.aihta.at/1382/</a> |
| Selinexor (Nexpovio®) in combination with bortezomib and dexamethasone for the treatment of multiple myeloma (MM)                                                                                                                                | published | 98  | 2022 | <a href="https://eprints.aihta.at/1384/">https://eprints.aihta.at/1384/</a> |
| Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB, IIC or III melanoma who have undergone complete resection                                                  | published | 99  | 2022 | <a href="https://eprints.aihta.at/1385/">https://eprints.aihta.at/1385/</a> |
| Melphalan flufenamide (Pepaxti®) with dexamethasone for the treatment of multiple myeloma (MM)                                                                                                                                                   | published | 100 | 2022 | <a href="https://eprints.aihta.at/1395/">https://eprints.aihta.at/1395/</a> |
| Asciminib (Scemblis®) for the treatment of Philadelphia chromosome?positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase (CP)                                                                                                          | published | 101 | 2022 | <a href="https://eprints.aihta.at/1396/">https://eprints.aihta.at/1396/</a> |
| Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer                                                                                                                     | published | 102 | 2022 | <a href="https://eprints.aihta.at/1397/">https://eprints.aihta.at/1397/</a> |
| Ibrutinib (Imbruvica®) in combination with venetoclax for the treatment of previously untreated chronic lymphocytic leukaemia (CLL)                                                                                                              | published | 103 | 2022 | <a href="https://eprints.aihta.at/1398/">https://eprints.aihta.at/1398/</a> |
| Olaparib (Lynparza®) as monotherapy or in combination with endocrine therapy for the adjuvant treatment of patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer                                        | published | 104 | 2022 | <a href="https://eprints.aihta.at/1399/">https://eprints.aihta.at/1399/</a> |
| Relatlimab/nivolumab (Opdulag®) for the first line treatment of advanced melanoma in adults and adolescents 12 years of age and older with tumour cell PD-L1 expression < 1%                                                                     | published | 105 | 2022 | <a href="https://eprints.aihta.at/1403/">https://eprints.aihta.at/1403/</a> |
| Autologous anti-CD19-transduced CD3+ cells (Tecartus®) for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL)                                            | published | 106 | 2022 | <a href="https://eprints.aihta.at/1404/">https://eprints.aihta.at/1404/</a> |
| Teclistamab (Tecvayi®) as monotherapy for the treatment of patients with relapsed and refractory multiple myeloma (MM) who have received at least three prior therapies                                                                          | published | 107 | 2022 | <a href="https://eprints.aihta.at/1405/">https://eprints.aihta.at/1405/</a> |
| Selpercatinib (Retsevmo®) as monotherapy for the treatment of adults and adolescents 12 years and older with advanced RET mutant medullary thyroid cancer (MTC)                                                                                  | published | 108 | 2022 | <a href="https://eprints.aihta.at/1406/">https://eprints.aihta.at/1406/</a> |
| Loncastuximab tesirine (Zynlonta®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)                                                                        | published | 109 | 2022 | <a href="https://eprints.aihta.at/1409/">https://eprints.aihta.at/1409/</a> |
| Zanubrutinib (Brukinsa®) as monotherapy for the treatment of marginal zone lymphoma (MZL)                                                                                                                                                        | published | 110 | 2022 | <a href="https://eprints.aihta.at/1410/">https://eprints.aihta.at/1410/</a> |
| Axicabtagene ciloleucel (Yescarta®) for the treatment of patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)                                                                                               | published | 111 | 2022 | <a href="https://eprints.aihta.at/1411/">https://eprints.aihta.at/1411/</a> |
| Zanubrutinib (Brukinsa®) as monotherapy for the treatment of adult patients with chronic lymphocytic leukaemia (CLL)                                                                                                                             | published | 112 | 2022 | <a href="https://eprints.aihta.at/1412/">https://eprints.aihta.at/1412/</a> |
| Cemiplimab (Libtayo®) as monotherapy for the treatment of recurrent or metastatic cervical cancer                                                                                                                                                | published | 113 | 2022 | <a href="https://eprints.aihta.at/1413/">https://eprints.aihta.at/1413/</a> |
| Lutetium (177Lu) vipivotide tetraxetan (Pluvicto®) in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition for the treatment of metastatic castration-resistant prostate cancer (mCRPC) | published | 114 | 2022 | <a href="https://eprints.aihta.at/1414/">https://eprints.aihta.at/1414/</a> |
| Trastuzumab deruxtecan (Enhertu®) for Gastric or gastroesophageal junction (GEJ) adenocarcinoma                                                                                                                                                  | published | 115 | 2022 | <a href="https://eprints.aihta.at/1421/">https://eprints.aihta.at/1421/</a> |
| Durvalumab (Imfinzi®) for Biliary tract cancer                                                                                                                                                                                                   | published | 116 | 2022 | <a href="https://eprints.aihta.at/1422/">https://eprints.aihta.at/1422/</a> |
| Olaparib (Lynparza®) for mCRPC                                                                                                                                                                                                                   | published | 117 | 2023 | <a href="https://eprints.aihta.at/1424/">https://eprints.aihta.at/1424/</a> |
| Tremelimumab (Imjudo®) + Durvalumab (Imfinzi®) for HCC                                                                                                                                                                                           | published | 118 | 2023 | <a href="https://eprints.aihta.at/1425/">https://eprints.aihta.at/1425/</a> |
| Tremelimumab (Tremelimumab AstraZeneca®) + Durvalumab (Imfinzi®) + Chemotherapy for NSCLC                                                                                                                                                        | published | 119 | 2023 | <a href="https://eprints.aihta.at/1426/">https://eprints.aihta.at/1426/</a> |
| Trastuzumab deruxtecan (Enhertu®) for HER2-low breast cancer                                                                                                                                                                                     | published | 120 | 2023 | <a href="https://eprints.aihta.at/1427/">https://eprints.aihta.at/1427/</a> |
| Nadofaragen Firadenovec (Adstiladrin®) for Bladder cancer                                                                                                                                                                                        | published | 121 | 2023 | <a href="https://eprints.aihta.at/1429/">https://eprints.aihta.at/1429/</a> |
| Oportuzumab monatox (Vicineum®) for Bladder cancer                                                                                                                                                                                               | published | 122 | 2023 |                                                                             |
| Darolutamide (Nubeqa®) in combination with docetaxel and androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC)                                                                            | published | 123 | 2023 | <a href="https://eprints.aihta.at/1429/">https://eprints.aihta.at/1429/</a> |
| Cipaglucosidase alfa (Pombiliti®) in combination with Miglustat for the treatment of adults with late-onset Pompe disease (acid alpha-glucosidase [GAA] deficiency)                                                                              | published | 124 | 2023 | <a href="https://eprints.aihta.at/1430/">https://eprints.aihta.at/1430/</a> |
| Niraparib/abiraterone acetate (Akeega®) for the treatment of metastatic castration-resistant prostate cancer (mCRPC)                                                                                                                             | published | 125 | 2023 | <a href="https://eprints.aihta.at/1432/">https://eprints.aihta.at/1432/</a> |
| Ivosidenib (Tibsovo®, Tidhesco®) in combination with azacitidine for the treatment of newly diagnosed acute myeloid leukaemia (AML)                                                                                                              | published | 126 | 2023 | <a href="https://eprints.aihta.at/1433/">https://eprints.aihta.at/1433/</a> |
| Ivosidenib (Tibsovo®) monotherapy for the treatment of locally advanced or metastatic cholangiocarcinoma                                                                                                                                         | published | 127 | 2023 | <a href="https://eprints.aihta.at/1438/">https://eprints.aihta.at/1438/</a> |
| Cemiplimab (Libtayo®) in combination with platinum-based chemotherapy for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)                                                                          | published | 128 | 2023 | <a href="https://eprints.aihta.at/1439/">https://eprints.aihta.at/1439/</a> |
| Lisocabtagene maraleucel (Breyanzi®) for the treatment of diffuse large B-cell lymphoma (DLBCL), high grade B cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B). Update July 2023 | published | 129 | 2023 | <a href="https://eprints.aihta.at/1440/">https://eprints.aihta.at/1440/</a> |
| Glofitamab (Columvi®) as monotherapy for the treatment of relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)                                                                                                                     | published | 130 | 2023 | <a href="https://eprints.aihta.at/1441/">https://eprints.aihta.at/1441/</a> |

| Title                                                                                                                                                                                                                                                   | Status    | No. | Year | Download/Link                                                               |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|-----|------|-----------------------------------------------------------------------------|
| Pirtobrutinib (JaypircaTM) as monotherapy for the treatment of relapsed or refractory (R/R) mantle cell lymphoma (MCL)                                                                                                                                  | published | 131 | 2023 | <a href="https://eprints.aihta.at/1444/">https://eprints.aihta.at/1444/</a> |
| Futibatinib (Lytgobi®) for the treatment of locally advanced or metastatic cholangiocarcinoma                                                                                                                                                           | published | 132 | 2023 | <a href="https://eprints.aihta.at/1445/">https://eprints.aihta.at/1445/</a> |
| Nivolumab (Opdivo®) in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer (NSCLC)                                                                                                      | published | 133 | 2023 | <a href="https://eprints.aihta.at/1446/">https://eprints.aihta.at/1446/</a> |
| Piflufolostat (18F) (Pylclari®) for the diagnosis of prostate cancer                                                                                                                                                                                    | published | 134 | 2023 | <a href="https://eprints.aihta.at/1447/">https://eprints.aihta.at/1447/</a> |
| Tremelimumab (Imjudo®) with durvalumab (Imfinzi®) and platinum-based chemotherapy for the first-line treatment of metastatic non-small cell lung cancer (NSCLC)                                                                                         | published | 135 | 2023 | <a href="https://eprints.aihta.at/1449/">https://eprints.aihta.at/1449/</a> |
| Trifluridine / tipiracil (Lonsurf®, TAS-02) with bevacizumab for the treatment of metastatic colorectal cancer (CRC)                                                                                                                                    | published | 136 | 2023 | <a href="https://eprints.aihta.at/1450/">https://eprints.aihta.at/1450/</a> |
| Sacituzumab govitecan (Trodelvy®) for the treatment of unresectable or metastatic hormone receptor-positive, HER2-negative breast cancer                                                                                                                | published | 137 | 2023 | <a href="https://eprints.aihta.at/1458/">https://eprints.aihta.at/1458/</a> |
| Crisantaspase (Enrylaze®) for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL)                                                                                                                                     | published | 138 | 2023 | <a href="https://eprints.aihta.at/1459/">https://eprints.aihta.at/1459/</a> |
| Cedazuridine/decitabine (Inaqovi®) for the treatment of newly diagnosed acute myeloid leukaemia (AML)                                                                                                                                                   | published | 139 | 2023 | <a href="https://eprints.aihta.at/1460/">https://eprints.aihta.at/1460/</a> |
| Elacestrant (Orserdu®) monotherapy for the treatment of oestrogen receptor (ER)?positive, HER2-negative, locally advanced or metastatic breast cancer                                                                                                   | published | 140 | 2023 | <a href="https://eprints.aihta.at/1462/">https://eprints.aihta.at/1462/</a> |
| Talquetamab (Talvey®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM)                                                                                                                                            | published | 141 | 2023 | <a href="https://eprints.aihta.at/1463/">https://eprints.aihta.at/1463/</a> |
| Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL)                                                                                                                                | published | 142 | 2023 | <a href="https://eprints.aihta.at/1464/">https://eprints.aihta.at/1464/</a> |
| Tislelizumab (Tevimbra®) as monotherapy for the treatment of unresectable, locally advanced, or metastatic oesophageal squamous cell carcinoma (OSCC)                                                                                                   | published | 143 | 2023 | <a href="https://eprints.aihta.at/1465/">https://eprints.aihta.at/1465/</a> |
| Nivolumab (Opdivo®) as monotherapy for the adjuvant treatment of Stage IIB or IIC melanoma, or melanoma with involvement of lymph nodes or metastatic disease                                                                                           | published | 144 | 2023 | <a href="https://eprints.aihta.at/1466/">https://eprints.aihta.at/1466/</a> |
| Pembrolizumab (Keytruda®) with trastuzumab, fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction (GEJ) adenocarcinoma | published | 145 | 2023 | <a href="https://eprints.aihta.at/1467/">https://eprints.aihta.at/1467/</a> |
| Trastuzumab deruxtecan (Enhertu®) as monotherapy for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumours have an activating HER2 (ERBB2) mutation                                                                  | published | 147 | 2023 | <a href="https://eprints.aihta.at/1468/">https://eprints.aihta.at/1468/</a> |
| Pembrolizumab (Keytruda®) as monotherapy for the adjuvant treatment of non-small cell lung carcinoma (NSCLC)                                                                                                                                            | published | 148 | 2023 | <a href="https://eprints.aihta.at/1469/">https://eprints.aihta.at/1469/</a> |
| Melphalan flufenamide (Pepaxti®) in combination with dexamethasone for the treatment of multiple myeloma (MM)                                                                                                                                           | published | 149 | 2023 | <a href="https://eprints.aihta.at/1472/">https://eprints.aihta.at/1472/</a> |
| Quizartinib (Vanflyta®) in combination with standard cytarabine and anthracycline induction and cytarabine consolidation chemotherapy, followed by single-agent maintenance therapy for patients with newly diagnosed acute myeloid leukaemia (AML)     | published | 150 | 2023 | <a href="https://eprints.aihta.at/1473/">https://eprints.aihta.at/1473/</a> |
| Zanubrutinib (Brukinsa®) with obinutuzumab for the treatment of refractory or relapsed follicular lymphoma (FL)                                                                                                                                         | published | 151 | 2023 | <a href="https://eprints.aihta.at/1474/">https://eprints.aihta.at/1474/</a> |
| Elranatamab (Elirexio®) as monotherapy for the treatment of relapsed and refractory multiple myeloma (MM)                                                                                                                                               | published | 152 | 2023 | <a href="https://eprints.aihta.at/1475/">https://eprints.aihta.at/1475/</a> |
| Durvalumab (Imfinzi®) as monotherapy for the first line treatment of advanced or unresectable hepatocellular carcinoma (HCC)                                                                                                                            | published | 153 | 2023 | <a href="https://eprints.aihta.at/1476/">https://eprints.aihta.at/1476/</a> |
| Dostarlimab (Jemperli®) with carboplatin and paclitaxel for the treatment of mismatch repair deficient (dMMR)/ microsatellite instability high (MSI-H) primary advanced or recurrent endometrial cancer (EC)                                            | published | 154 | 2023 | <a href="https://eprints.aihta.at/1479/">https://eprints.aihta.at/1479/</a> |
| Pembrolizumab (Keytruda®) with fluoropyrimidine and platinum-containing chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma                    | published | 155 | 2023 | <a href="https://eprints.aihta.at/1480/">https://eprints.aihta.at/1480/</a> |
| Rucaparib (Rubraca®) as monotherapy for the maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer                                                                                               | published | 156 | 2023 | <a href="https://eprints.aihta.at/1481/">https://eprints.aihta.at/1481/</a> |
| Avapritinib (Ayvakyt®) for the treatment of indolent systemic mastocytosis (ISM)                                                                                                                                                                        | published | 157 | 2023 | <a href="https://eprints.aihta.at/1482/">https://eprints.aihta.at/1482/</a> |
| Pembrolizumab (Keytruda®) with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma (BTC)                                                                                      | published | 158 | 2023 | <a href="https://eprints.aihta.at/1483/">https://eprints.aihta.at/1483/</a> |
| Adagrasib (Krazati®) as monotherapy for the treatment of advanced non-small cell lung cancer (NSCLC)                                                                                                                                                    | published | 159 | 2023 | <a href="https://eprints.aihta.at/1484/">https://eprints.aihta.at/1484/</a> |
| essential thrombocythaemia myelofibrosis                                                                                                                                                                                                                | published | 160 | 2023 | <a href="https://eprints.aihta.at/1491/">https://eprints.aihta.at/1491/</a> |
| Talazoparib (Talzenna®) in combination with enzalutamide for the treatment of metastatic castration-resistant prostate cancer (mCRPC)                                                                                                                   | published | 161 | 2023 | <a href="https://eprints.aihta.at/1492/">https://eprints.aihta.at/1492/</a> |
| Idecabtagene vicleucel (Abecma®) for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies                                                                                  | published | 162 | 2024 | <a href="https://eprints.aihta.at/1493/">https://eprints.aihta.at/1493/</a> |
| Selpercatinib (Retsevmo®) as monotherapy is indicated for the treatment of adults and adolescents with advanced RET fusion-positive thyroid cancer                                                                                                      | published | 163 | 2024 | <a href="https://eprints.aihta.at/1494/">https://eprints.aihta.at/1494/</a> |
| Tislelizumab (Tizveni®) in monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)                                                                                       | published | 164 | 2024 | <a href="https://eprints.aihta.at/1495/">https://eprints.aihta.at/1495/</a> |
| Retifanlimab (Zynyz®) as monotherapy for the first line treatment of patients with metastatic or recurrent locally advanced Merkel cell carcinoma                                                                                                       | published | 165 | 2024 | <a href="https://eprints.aihta.at/1507/">https://eprints.aihta.at/1507/</a> |
| Ciltacabtagene autoleucel (Carvykti®) for the treatment of relapsed and refractory multiple myeloma (MM)                                                                                                                                                | published | 166 | 2024 | <a href="https://eprints.aihta.at/1508/">https://eprints.aihta.at/1508/</a> |
| Pembrolizumab (Keytruda®) as pre- and post-operative treatment of resectable non small cell lung carcinoma (NSCLC)                                                                                                                                      | published | 167 | 2024 | <a href="https://eprints.aihta.at/1509/">https://eprints.aihta.at/1509/</a> |
| Irinotecan hydrochloride trihydrate (Onivyde® pegylated liposomal) in combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas             | published | 168 | 2024 | <a href="https://eprints.aihta.at/1510/">https://eprints.aihta.at/1510/</a> |
| Selpercatinib (Retsevmo®) as monotherapy for the treatment of advanced rearranged during transfection (RET) fusion-positive solid tumours                                                                                                               | published | 169 | 2024 | <a href="https://eprints.aihta.at/1511/">https://eprints.aihta.at/1511/</a> |
| Enzalutamide (Xtandi®) as monotherapy or in combination with androgen deprivation therapy (ADT) for the treatment of high risk biochemical recurrent (BCR) non-metastatic hormone sensitive prostate cancer (nmHSPC)                                    | published | 170 | 2024 | <a href="https://eprints.aihta.at/1512/">https://eprints.aihta.at/1512/</a> |
| Fruquintinib (Fruzaqla®) as monotherapy for the treatment of metastatic colorectal cancer (mCRC)                                                                                                                                                        | published | 171 | 2024 | <a href="https://eprints.aihta.at/1515/">https://eprints.aihta.at/1515/</a> |
| Capivasertib (Truqap®) with fulvestrant for the treatment ER-positive, HER2 negative locally advanced or metastatic breast cancer                                                                                                                       | published | 172 | 2024 | <a href="https://eprints.aihta.at/1516/">https://eprints.aihta.at/1516/</a> |
| Alectinib (Alecensa®) as adjuvant treatment following complete tumour resection for adult patients with ALK positive non-small cell lung cancer (NSCLC)                                                                                                 | published | 173 | 2024 | <a href="https://eprints.aihta.at/1517/">https://eprints.aihta.at/1517/</a> |
| Nivolumab (Opdivo®) in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma                                                                                                       | published | 174 | 2024 | <a href="https://eprints.aihta.at/1518/">https://eprints.aihta.at/1518/</a> |
| Entrectinib (Rozlytrek®) as monotherapy for the treatment of solid tumours with a NTRK gene fusion                                                                                                                                                      | published | 175 | 2024 | <a href="https://eprints.aihta.at/1519/">https://eprints.aihta.at/1519/</a> |
| Amivantamab (Rybrevant®) with carboplatin and pemetrexed for the first line treatment of advanced non-small cell lung cancer (NSCLC) with activating EGFR Exon 20 insertion mutations                                                                   | published | 176 | 2024 | <a href="https://eprints.aihta.at/1520/">https://eprints.aihta.at/1520/</a> |
| Sugemalimab (Cejemly®) with platinum-based chemotherapy for the first?line treatment of metastatic non-small-cell lung cancer (NSCLC)                                                                                                                   | published | 177 | 2024 | <a href="https://eprints.aihta.at/1521/">https://eprints.aihta.at/1521/</a> |
| Osimertinib (Tagrisso®) with pemetrexed and platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer (NSCLC)                                                                                                     | published | 178 | 2024 | <a href="https://eprints.aihta.at/1522/">https://eprints.aihta.at/1522/</a> |
| Tislelizumab (Tevimbra®) monotherapy or in combination with chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC)                                                                                         | published | 179 | 2024 | <a href="https://eprints.aihta.at/1523/">https://eprints.aihta.at/1523/</a> |

| Title                                                                                                                                                                                                                                                                                                                                                                         | Status     | No. | Year | Download/Link                                                               |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|------|-----------------------------------------------------------------------------|
| Erdaftinitib (Balversa®) as monotherapy for the treatment of unresectable or metastatic urothelial carcinoma (UC)                                                                                                                                                                                                                                                             | published  | 180 | 2024 | <a href="https://eprints.aihta.at/1531/">https://eprints.aihta.at/1531/</a> |
| Odonexlamab (Ordospono®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (r/r FL) or diffuse large B?cell lymphoma (r/r DLBCL)                                                                                                                                                                                                                 | published  | 181 | 2024 | <a href="https://eprints.aihta.at/1532/">https://eprints.aihta.at/1532/</a> |
| Durvalumab (Imfinzi®) in combination with carboplatin and paclitaxel for the first-line treatment of primary advanced or recurrent endometrial cancer (EC), followed by maintenance treatment durvalumab (Imfinzi®) as monotherapy in EC that is mismatch repair deficient (dMMR) or in combination with olaparib (Lynparza®) in EC that is mismatch repair proficient (pMMR) | published  | 182 | 2024 | <a href="https://eprints.aihta.at/1533/">https://eprints.aihta.at/1533/</a> |
| Epcoritamab (Tepkinly®) as monotherapy for the treatment of relapsed or refractory follicular lymphoma (FL)                                                                                                                                                                                                                                                                   | published  | 183 | 2024 | <a href="https://eprints.aihta.at/1534/">https://eprints.aihta.at/1534/</a> |
| Toripalimab (Loqtorzi®) in combination with cisplatin and gemcitabine for the first-line treatment of recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma (NPC)                                                                                                                                                                        | published  | 184 | 2024 | <a href="https://eprints.aihta.at/1537/">https://eprints.aihta.at/1537/</a> |
| Toripalimab (Loqtorzi®) with cisplatin and paclitaxel for the first-line treatment of unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC)                                                                                                                                                                                              | published  | 185 | 2024 | <a href="https://eprints.aihta.at/1538/">https://eprints.aihta.at/1538/</a> |
| Zolbetuximab (Vyloy®) with chemotherapy for the first-line treatment of locally advanced unresectable or metastatic HER2?negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma                                                                                                                                                                                 | published  | 186 | 2024 | <a href="https://eprints.aihta.at/1539/">https://eprints.aihta.at/1539/</a> |
| Encorafenib (Braftovi®) in combination with binimetinib (Mektovi®) for the treatment of advanced non-small cell lung cancer (NSCLC)                                                                                                                                                                                                                                           | published  | 187 | 2024 | <a href="https://eprints.aihta.at/1540/">https://eprints.aihta.at/1540/</a> |
| Pembrolizumab (Keytruda®) with enfortumab vedotin (Padcev®) for the first-line treatment of unresectable or metastatic urothelial carcinoma                                                                                                                                                                                                                                   | published  | 188 | 2024 | <a href="https://eprints.aihta.at/1541/">https://eprints.aihta.at/1541/</a> |
| Amivantamab (Rybrentav®) in combination with carboplatin and pemetrexed for the treatment of advanced non-small cell lung cancer (NSCLC)                                                                                                                                                                                                                                      | published  | 189 | 2024 | <a href="https://eprints.aihta.at/1542/">https://eprints.aihta.at/1542/</a> |
| Atezolizumab (Tecentriq®) as monotherapy for the first-line treatment of advanced NSCLC                                                                                                                                                                                                                                                                                       | published  | 190 | 2024 | <a href="https://eprints.aihta.at/1543/">https://eprints.aihta.at/1543/</a> |
| Daratumumab (Darzalex®) with bortezomib, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM)                                                                                                                                                                                                                                            | published  | 191 | 2024 | <a href="https://eprints.aihta.at/1550/">https://eprints.aihta.at/1550/</a> |
| Serplulimab (Hetrionfly®) with carboplatin and etoposide for the first?line treatment of extensive?stage small cell lung cancer (ES-SCLC)                                                                                                                                                                                                                                     | published  | 192 | 2024 | <a href="https://eprints.aihta.at/1551/">https://eprints.aihta.at/1551/</a> |
| Mirvetuximab soravtansine (Elahere®) for the treatment of adults with folate receptor-alpha (FR?) positive epithelial ovarian, fallopian tube and primary peritoneal cancer                                                                                                                                                                                                   | published  | 193 | 2024 | <a href="https://eprints.aihta.at/1552/">https://eprints.aihta.at/1552/</a> |
| Pembrolizumab (Keytruda®) with chemoradiotherapy (CRT) for the treatment of FIGO 2014 Stage III - IVA locally advanced cervical cancer                                                                                                                                                                                                                                        | published  | 194 | 2024 | <a href="https://eprints.aihta.at/1553/">https://eprints.aihta.at/1553/</a> |
| Pembrolizumab (Keytruda®) for the treatment of adults with endometrial carcinoma                                                                                                                                                                                                                                                                                              | published  | 195 | 2024 | <a href="https://eprints.aihta.at/1554/">https://eprints.aihta.at/1554/</a> |
| Catumaxomab (Korjuni®) for the treatment of malignant ascites                                                                                                                                                                                                                                                                                                                 | published  | 196 | 2025 | <a href="https://eprints.aihta.at/1578/">https://eprints.aihta.at/1578/</a> |
| Tislelizumab (Tevimbra®) with platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma                                                                                                                                                                                                    | publiziert | 198 | 2025 | <a href="https://eprints.aihta.at/1579/">https://eprints.aihta.at/1579/</a> |
| Tislelizumab (Tevimbra®) with chemotherapy for the first-line treatment of HER-2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma                                                                                                                                                                                        | publiziert | 199 | 2025 | <a href="https://eprints.aihta.at/1582/">https://eprints.aihta.at/1582/</a> |
| Pembrolizumab (Keytruda®) for the treatment of malignant pleural mesothelioma                                                                                                                                                                                                                                                                                                 | publiziert | 202 | 2025 | <a href="https://eprints.aihta.at/1583/">https://eprints.aihta.at/1583/</a> |
| Blinatumomab (Blincyto®) monotherapy as part of consolidation therapy for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL)                                                                                                                                                      | publiziert | 208 | 2025 | <a href="https://eprints.aihta.at/1584/">https://eprints.aihta.at/1584/</a> |
| Datopotamab deruxtecan (Datroway®) for the treatment of unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer                                                                                                                                                                                   | publiziert | 210 | 2025 | <a href="https://eprints.aihta.at/1580/">https://eprints.aihta.at/1580/</a> |
| Lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy                                                                                                                                                                                                          | publiziert | 212 | 2025 | <a href="https://eprints.aihta.at/1588/">https://eprints.aihta.at/1588/</a> |
| Tislelizumab (Tevimbra®) with etoposide and platinum chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer                                                                                                                                                                                                                                      | publiziert | 225 | 2025 | <a href="https://eprints.aihta.at/1585/">https://eprints.aihta.at/1585/</a> |
| Tislelizumab (Tevimbra®) in combination with gemcitabine and cisplatin for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma                                                                                                                                                                                                                       | publiziert | 233 | 2025 | <a href="https://eprints.aihta.at/1586/">https://eprints.aihta.at/1586/</a> |
| Tislelizumab (Tevimbra®) with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer                                                                                                                                               | publiziert | 241 | 2025 | <a href="https://eprints.aihta.at/1587/">https://eprints.aihta.at/1587/</a> |
| <b>Other Reports/ Projects</b>                                                                                                                                                                                                                                                                                                                                                |            |     |      |                                                                             |
| Annual Report 2006. German version.                                                                                                                                                                                                                                                                                                                                           | published  |     | 2007 | <a href="http://eprints.aihta.at/781/">http://eprints.aihta.at/781/</a>     |
| Annual Report 2006. English version.                                                                                                                                                                                                                                                                                                                                          | published  |     | 2007 | <a href="http://eprints.aihta.at/786/">http://eprints.aihta.at/786/</a>     |
| Annual Report 2007. German version.                                                                                                                                                                                                                                                                                                                                           | published  |     | 2008 | <a href="http://eprints.aihta.at/782/">http://eprints.aihta.at/782/</a>     |
| Annual Report 2007. English version.                                                                                                                                                                                                                                                                                                                                          | published  |     | 2008 | <a href="http://eprints.aihta.at/785/">http://eprints.aihta.at/785/</a>     |
| Annual Report 2008. German version.                                                                                                                                                                                                                                                                                                                                           | published  |     | 2009 | <a href="http://eprints.aihta.at/819/">http://eprints.aihta.at/819/</a>     |
| Annual Report 2008. English version.                                                                                                                                                                                                                                                                                                                                          | published  |     | 2009 | <a href="http://eprints.aihta.at/821/">http://eprints.aihta.at/821/</a>     |
| Annual Report 2009. German version.                                                                                                                                                                                                                                                                                                                                           | published  |     | 2010 | <a href="http://eprints.aihta.at/871/">http://eprints.aihta.at/871/</a>     |
| Annual Report 2009. English version.                                                                                                                                                                                                                                                                                                                                          | published  |     | 2010 | <a href="http://eprints.aihta.at/872/">http://eprints.aihta.at/872/</a>     |
| Annual Report 2010. German version.                                                                                                                                                                                                                                                                                                                                           | published  |     | 2011 | <a href="http://eprints.aihta.at/904/">http://eprints.aihta.at/904/</a>     |
| Annual Report 2010. English version.                                                                                                                                                                                                                                                                                                                                          | published  |     | 2011 | <a href="http://eprints.aihta.at/909/">http://eprints.aihta.at/909/</a>     |
| Annual Report 2011. German version.                                                                                                                                                                                                                                                                                                                                           | published  |     | 2012 | <a href="http://eprints.aihta.at/943/">http://eprints.aihta.at/943/</a>     |
| Annual Report 2011. English version.                                                                                                                                                                                                                                                                                                                                          | published  |     | 2012 | <a href="http://eprints.aihta.at/944/">http://eprints.aihta.at/944/</a>     |
| "Institut für Health Technology Assessment" unter Mitfinanzierung der Ludwig Boltzmann Gesellschaft 2013-2020                                                                                                                                                                                                                                                                 | finished   |     | 2010 | not published                                                               |
| "Institute for Health Technology Assessment" with Co-financing of the Ludwig Boltzmann Gesellschaft 2013 bis 2020                                                                                                                                                                                                                                                             | finished   |     | 2011 | not published                                                               |
| Annual Report 2012. German/English                                                                                                                                                                                                                                                                                                                                            | published  |     | 2013 | <a href="http://eprints.aihta.at/991/">http://eprints.aihta.at/991/</a>     |
| Annual Report 2013. German/English                                                                                                                                                                                                                                                                                                                                            | published  |     | 2014 | <a href="http://eprints.aihta.at/1022/">http://eprints.aihta.at/1022/</a>   |
| Annual Report 2014. German/English                                                                                                                                                                                                                                                                                                                                            | published  |     | 2015 | <a href="http://eprints.aihta.at/1048/">http://eprints.aihta.at/1048/</a>   |
| Annual Report 2015. German/English                                                                                                                                                                                                                                                                                                                                            | published  |     | 2016 | <a href="http://eprints.aihta.at/1083/">http://eprints.aihta.at/1083/</a>   |
| Annual Report 2016. German/English                                                                                                                                                                                                                                                                                                                                            | published  |     | 2017 | <a href="http://eprints.aihta.at/1150/">http://eprints.aihta.at/1150/</a>   |
| Annual Report 2017. German/English                                                                                                                                                                                                                                                                                                                                            | published  |     | 2018 | <a href="http://eprints.aihta.at/1151/">http://eprints.aihta.at/1151/</a>   |

| Title                                                                                                                         | Status    | No. | Year                       | Download/Link                                                               |
|-------------------------------------------------------------------------------------------------------------------------------|-----------|-----|----------------------------|-----------------------------------------------------------------------------|
| Annual Report 2018. German/English                                                                                            | published |     | 2019                       | <a href="http://eprints.aihta.at/1187/">http://eprints.aihta.at/1187/</a>   |
| Annual Report 2019. German/English                                                                                            | published |     | 2020                       | <a href="http://eprints.aihta.at/1226/">http://eprints.aihta.at/1226/</a>   |
| Annual Report 2020. German/English                                                                                            | published |     | 2021                       | <a href="https://eprints.aihta.at/1294/">https://eprints.aihta.at/1294/</a> |
| Annual Report 2021. German/English                                                                                            | published |     | 2022                       | <a href="https://eprints.aihta.at/1358/">https://eprints.aihta.at/1358/</a> |
| Annual Report 2022. German/English                                                                                            | published |     | 2023                       | <a href="https://eprints.aihta.at/1423/">https://eprints.aihta.at/1423/</a> |
| Annual Report 2023. German/English                                                                                            | published |     | 2024                       | <a href="https://eprints.aihta.at/1501/">https://eprints.aihta.at/1501/</a> |
| Annual Report 2024. German/English                                                                                            | published |     | 2025                       | <a href="https://eprints.aihta.at/1557/">https://eprints.aihta.at/1557/</a> |
|                                                                                                                               |           |     |                            |                                                                             |
| EUnetHTA (European network for Health Technology Assessment) Joint Action 1 - Lead Partner Work package 7B - New Technologies | ongoing   |     | 2006-2008, 2009, 2010-2013 | <a href="http://www.eunetha.eu/">www.eunetha.eu/</a>                        |
| EUnetHTA (European network for Health Technology Assessment) Joint Action 2 - Colead Partner Work package 5 - Collaboration   | ongoing   |     | 2012-2015                  | <a href="http://www.eunetha.eu/">www.eunetha.eu/</a>                        |
| AdHopHTA                                                                                                                      | ongoing   |     | 2012-2015                  | <a href="http://www.adhophta.eu/">http://www.adhophta.eu/</a>               |
| HSO Priorisation No. 18                                                                                                       | published |     | 2014                       | <a href="http://eprints.aihta.at/1026/">http://eprints.aihta.at/1026/</a>   |
| HSO Priorisation No. 19                                                                                                       | published |     | 2014                       | <a href="http://eprints.aihta.at/1033/">http://eprints.aihta.at/1033/</a>   |
| HSO Priorisation No. 20                                                                                                       | published |     | 2014                       | <a href="http://eprints.aihta.at/1040/">http://eprints.aihta.at/1040/</a>   |
| HSO Priorisation No. 21                                                                                                       | published |     | 2015                       | <a href="http://eprints.aihta.at/1046/">http://eprints.aihta.at/1046/</a>   |
| HSO Priorisation No. 22                                                                                                       | published |     | 2015                       | <a href="http://eprints.aihta.at/1052/">http://eprints.aihta.at/1052/</a>   |
| HSO Priorisation No. 23                                                                                                       | published |     | 2015                       | <a href="http://eprints.aihta.at/1065/">http://eprints.aihta.at/1065/</a>   |
| HSO Priorisation No. 24                                                                                                       | published |     | 2015                       | <a href="http://eprints.aihta.at/1074/">http://eprints.aihta.at/1074/</a>   |
| HSO Priorisation No. 25                                                                                                       | published |     | 2016                       | <a href="http://eprints.aihta.at/1079/">http://eprints.aihta.at/1079/</a>   |
| HSO Priorisation No. 26                                                                                                       | published |     | 2016                       | <a href="http://eprints.aihta.at/1087/">http://eprints.aihta.at/1087/</a>   |
| HSO Priorisation No. 27                                                                                                       | published |     | 2016                       | <a href="http://eprints.aihta.at/1099/">http://eprints.aihta.at/1099/</a>   |
| HSO Priorisation No. 28                                                                                                       | published |     | 2016                       | <a href="http://eprints.aihta.at/1106/">http://eprints.aihta.at/1106/</a>   |
| HSO Priorisation No. 29                                                                                                       | published |     | 2017                       | <a href="http://eprints.aihta.at/1113/">http://eprints.aihta.at/1113/</a>   |
| HSO Priorisation No. 30                                                                                                       | published |     | 2017                       | <a href="http://eprints.aihta.at/1117/">http://eprints.aihta.at/1117/</a>   |
| HSO Priorisation No. 31                                                                                                       | published |     | 2017                       | <a href="http://eprints.aihta.at/1121/">http://eprints.aihta.at/1121/</a>   |
| HSO Priorisation No. 32                                                                                                       | published |     | 2017                       | <a href="http://eprints.aihta.at/1133/">http://eprints.aihta.at/1133/</a>   |
| HSO Priorisation No. 33                                                                                                       | published |     | 2018                       | <a href="http://eprints.aihta.at/1135/">http://eprints.aihta.at/1135/</a>   |
| HSO Priorisation No. 34                                                                                                       | published |     | 2018                       | <a href="http://eprints.aihta.at/1149/">http://eprints.aihta.at/1149/</a>   |
| HSO Priorisation No. 35                                                                                                       | published |     | 2018                       | <a href="http://eprints.aihta.at/1156/">http://eprints.aihta.at/1156/</a>   |
| HSO Priorisation No. 36                                                                                                       | published |     | 2018                       | <a href="http://eprints.aihta.at/1162/">http://eprints.aihta.at/1162/</a>   |
| HSO Priorisation No. 37                                                                                                       | published |     | 2018                       | <a href="http://eprints.aihta.at/1179/">http://eprints.aihta.at/1179/</a>   |
| HSO Priorisation No. 38                                                                                                       | published |     | 2019                       | <a href="http://eprints.aihta.at/1189/">http://eprints.aihta.at/1189/</a>   |
| HSO Priorisation No. 39                                                                                                       | published |     | 2019                       | <a href="http://eprints.aihta.at/1196/">http://eprints.aihta.at/1196/</a>   |
| HSO Priorisation No. 40                                                                                                       | published |     | 2019                       | <a href="http://eprints.aihta.at/1208/">http://eprints.aihta.at/1208/</a>   |
| HSO Priorisation No. 41                                                                                                       | published |     | 2020                       | <a href="http://eprints.aihta.at/1220/">http://eprints.aihta.at/1220/</a>   |